University of Massachusetts Amherst

ScholarWorks@UMass Amherst
Open Access Dissertations
5-13-2011

The Roles of Notch1 and PKC-Θ
PKC- in Immune Mediated Bone
Marrow Failure
Justine E. Roderick
University of Massachusetts Amherst

Follow this and additional works at: https://scholarworks.umass.edu/open_access_dissertations
Part of the Animal Sciences Commons

Recommended Citation
Roderick, Justine E., "The Roles of Notch1 and PKC-Θ in Immune Mediated Bone Marrow Failure" (2011).
Open Access Dissertations. 416.
https://doi.org/10.7275/2176856 https://scholarworks.umass.edu/open_access_dissertations/416

This Open Access Dissertation is brought to you for free and open access by ScholarWorks@UMass Amherst. It
has been accepted for inclusion in Open Access Dissertations by an authorized administrator of
ScholarWorks@UMass Amherst. For more information, please contact scholarworks@library.umass.edu.

THE ROLES OF NOTCH1 AND PKC-Θ
IN IMMUNE MEDIATED BONE MARROW FAILURE

A Dissertation Presented

by
JUSTINE E. RODERICK

Submitted to the Graduate School of the
University of Massachusetts Amherst in partial fulfillment
of the requirements for the degree of
DOCTOR OF PHILOSOPHY
May 2011
Program in Animal Biotechnology and Biomedical Science

© Copyright by Justine E. Roderick
All Rights Reserved

THE ROLES OF NOTCH1 AND PKC-Θ
IN IMMUNE MEDIATED BONE MARROW FAILURE

A Dissertation Presented
By
JUSTINE E. RODERICK

Approved as to style and content by:

_____________________________
Lisa M. Minter, Chair

_______________________________
Barbara A. Osborne, Member

_______________________________
Juan Anguita, Member

_______________________________
Wilmore Webley, Member

______________________________________
Samuel Black, Department Head
Department of Veterinary and Animal Sciences

DEDICATION
To anyone who has ever lost a loved one to aplastic anemia, your stories have been the
inspirations for this research.

ACKNOWLEDGMENTS
It takes the support of an entire department, friends and family to make it through
the pains of graduate school. With that said there are many people I need to thank. First
and foremost I need to thank my mentor Lisa Minter she has provided all of the tools I
needed to become a confident scientist, a far cry from the insecure undergraduate I was
when I entered the program. In addition to being my advisor she has been like a second
mom to me, which I will always be grateful for. I also need to thank my second PI
Barbara Osborne. I’ve been lucky to have her presence in my scientific career, I’m glad
that she had faith in me when I was unsure of myself. The success of this research would
not have been possible without the support of my thesis committee and the entire VACSI
department. Although I began my career as an only child so to speak I now enjoy and
appreciate the company of my lab mates. I especially need to thank Tina, she has been an
excellent lab mate, friend and punching bag. In all seriousness she has become my little
sister and I will miss her dearly. Gaby has been a tremendous asset and instrumental in
completing my experiments and is by far the best “friend” checker I have ever had the
pleasure of knowing. All members of “Osguiter” quadrant have been great friends and
distraction makers. Who better to commiserate with than your fellow graduate students?!
Remember Minter lab “GO BIG OR GO HOME!” Last but certainly not least I need to
thank my family for all of their love and support including, but not limited to, my mother,
father and brother. They have listened to all of my relentless whining and scientific
findings over the past five years. I also have to thank my boyfriend Tim and our cohort of
furry children. I must say that no one has had to steady my hand more times or provide
more moral support than him; this body of work is proof of that.

v

ABSTRACT
THE ROLES OF NOTCH1 AND PKC-Θ IN IMMUNE MEDIATED BONE
MARROW FAILURE
May 2011
JUSTINE E RODERICK, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Lisa M. Minter
We sought to evaluate the individual contributions of Notch1 and PKC-ζ to
disease progression in a mouse model of immune-mediated bone marrow failure and to
define a mechanism for their potential cellular cooperation. We transferred parental bulk
splenocytes into F1-hybrid recipients to induce a robust immune-mediated bone marrow
failure (BMF) that we could partially rescue by administering a pharmacological inhibitor
of Notch activation. Transferring splenocytes from PKC-ζ-/- animals did not induce
disease, and treating animals with a pharmacological inhibitor of PKC-ζ also provided
full protection from disease. We found that inhibiting Notch1 resulted in PKC-ζ downregulation, and blocking PKC-ζ reduced Notch1 activation, possibly within a positive
feedback loop. Our data suggest that both Notch1 and PKC-ζ contribute to disease
progression in our mouse model of immune-mediated bone marrow failure. Furthermore,
additional findings from the lab demonstrated physical interactions between Notch1,
members of the T cell signalosome and PKC-ζ that are essential to mediating full
activation of T cells following signaling through the TCR and CD28. Notch1 and/or
PKC-ζ may represent novel therapeutic targets in the treatment of bone marrow failure.
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CHAPTER 1

INTRODUCTION

The adaptive immune system has developed evolutionarily into a complex system
that maintains self-tolerance while shielding the body against foreign invaders. Key
players in the regulation of the adaptive immune system are T cells. T cells are a subset
of lymphocytes which develop in the thymus and are known for their ability to identify a
diverse number of pathogens. Defects in self-tolerance can arise when there are
malfunction in the regulation of T cell development. In order to preserve the essential
machinery responsible for self-tolerance the adaptive immune system has developed a
series of selection phases to remove autoreactive T cells. Loss of self-tolerance can lead
to the activation and expansion of autoreactive T cells. As a result of this abnormal
activation of the immune system, autoimmunity may develop. Autoimmune disorders
result in the destruction of many different tissues by one’s own immune system.
For hundreds of years the thymus was an organ of unknown purpose, in fact there
were many studies which concluded that it had no immune function at all (Bilingham et
al. 1962). Today we know that the thymus is an essential organ in the immune system
that is responsible for T cell development. T cells begin their life in the bone marrow as a
result of hematopoiesis. Once they become common lymphoid progenitors (CLPs), T
cells migrate to the thymus where they develop into mature T cells. Part of the maturation
process is the elimination of autoreactive T cells. Autoreactive T cells are removed
through two processes, positive and negative selection. In the thymus T cells encounter
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antigen presenting cells such as epithelial cells, dendritic cells and macrophages, which
present antigens, in the context of the major histocompatibility complexes, to the T cells.
During positive selection immature T cells are probed for their ability to bind self MHC.
T cells that lack the ability to bind self MHC will receive a signal to undergo apoptosis. T
cells that survive positive selection then undergo negative selection, which is vital to
maintaining self-tolerance. During negative selection T cells that have high-affinity
receptors for self-MHC with or without self-antigen will undergo apoptosis. These
processes effectively remove any T cells that responded to self, thus preventing the
development of an autoimmune disorder. There is one exception in this process that leads
to the development of regulatory T cells. The exact mechanisms and time line of positive
and negative selection are not completely defined, but it is believed that in some cases
they occur simultaneously.
T cell-mediated autoimmune disorders are believed to arise after an initiating
event. An example of an initiating event is the exposure to a virus, which presents an
antigen that leads to development of autoreactive T cells. It is also hypothesized that
patients that develop autoimmune disorders have an underlying predisposition which
contributes to the disease development. Each autoimmune disorder is unique in its target
organ, such as the beta cells in diabetes or the central nervous system in multiple
sclerosis. Although each of these diseases varies in origin and targeted tissue destruction,
T cells appear to play an important role in mediating disease.
The objective of this dissertation is to dissect T cell activation and polarization as
they occur in the context of autoimmune disorders, such as Aplastic Anemia (AA).
Although there are many mechanism that are important in T cell activation and
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polarization, the focus of these experiments is on molecules that have been documented
to play a role in the development of a TH1 phenotype. The results from these studies may
potentially lead to the discovery of new therapeutics that can inhibit T cell activation,
dampening immune responses which, in turn, reduce self-mediated destruction in
autoimmune disorders.

1.1 T Cell Function and Differentiation

1.1.1 T Cell Activation

Mature T cells become activated when there is engagement of their T cell receptor
(TCR) by a foreign peptide. The peptide is presented to the T cell in a self-MHC
molecule that is recognized by either the CD4 or CD8 receptor. To achieve robust
activation T cells require a co-stimulatory signal. The major co-stimulatory receptor on T
cells is CD28. CD28 binds to its co-stimulatory ligand, CD80/CD86, on antigen
presenting cells (APC) (Chambers and Allison, 1999). Once the T cell receives the
appropriate signals there is a cascade of phosphorylation events that leads to the
activation of downstream genes, such as il2. In this cascade Zap70 signals to several
adaptor molecules, including LAT, SLP76, Vav, Grbz, PI3K, and PLCγ-1 (Lin et al.,
2004). Ultimately these signals aid in mediating the formation of the immunological
synapse which is required for sustained TCR engagement with antigen presenting cells
(Valittui et al., 1995). T cell activation regulates several key transcription factors such as
activated protein-1 (AP-1), nuclear factor of activated T cell (NFAT) and nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB). These transcription factors are
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vital to maintaining T cell expansion through the production of the cytokine interleukin-2
(IL-2).

1.1.2 T Cell Subsets

T cells are divided into two major groups based on the MHC class type that they
recognize. CD4+ T helper cells express the receptor CD4 which recognizes class II MHC
that is present on APCs. CD4+ T cells can develop into a series of different types of T
helper cells, outlined in Figure 1.1, including but not limited to TH1, TH2, TH17, Tregs.
CD8+ cytotoxic T cells express the CD8 receptor which recognizes class I MHC
molecule that is expressed on the majority of cell types.
Once activated T helper cells mediate immune responses by secreting cytokines
that activate B cells and CD8+ cytotoxic T cells. T helper cells are characterized by the
cytokines that they produce as effector cells. Different CD4+ T cell subsets arise as a
result of the cytokine milieu which is present during their activation. TH1 cells are
responsible for the recognition of intracellular viruses and bacteria; they are also the
dominating cell type in the development of autoimmune bone marrow failure syndromes
(Solomou et al., 2006). TH1 cells secrete IFN-γ and are regulated by the transcription
factor tbx21 (T-bet) (Rangarajan et al., 1996; Szabo et al., 2000; Mosmann, 2006; Abbas,
2006). TH2 cells are required for humoral immunity and the removal of extracellular
pathogens. They produce IL-4 and IL-5 and are regulated by the transcription factor
gata3 (Zheng, Flavell, 1997). TH17 cells are a relatively newly-defined T cell subset that
produces proinflammatory cytokines such as IL-17 and IL-22 (Liang et al., 2006). They
aid in the clearance of extracellular bacteria and fungi. Additionally TH17 cells have been
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shown to play a role in autoimmune disorders such as multiple sclerosis (Mai et al.,
2010). TH17 cells are polarized under the transcription factor rorc (Ivanov et al., 2006). T
regulatory (Treg) cells differ from the other CD4+ helper subsets because their function is
to dampen immune responses that are associated with excessive inflammation and
autoimmunity (Kleinschek et al., 2010; Mai, 2010). Tregs are regulated by the
transcription factor foxp3 (Hori et al., 2003; Fontenot et al., 2003, Khatti et al., 2003).
Recently there has been the discovery of additional CD4+ T helper cells such as, T
follicular cells, TH9 and TH22.
CD8+ cytotoxic T lymphocytes (CTL) arise in a fashion similar to CD4+ cells but
have a completely different function. Unlike CD4+ cells CTLs have a lytic ability. CD8+
cells are crucial to the recognition and destruction of altered self-cells that are infected
with intracellular bacteria, virus or protozoa. CTLs have also been shown to mediated
tissue damage in autoimmune disorders, such as diabetes (Wang et al., 1991, Deckert et
al., 2010). Once CTLs are activated they have the capacity to release cytotoxic granules
and kill infected cells.
Within cytotoxic granules there are two proteins that regulate cell mediated
destruction. Granzymes are a family of distinct serine proteases that mediate cell death.
Granzyme B is the most abundant and, therefore, much of the research in the literature is
focused on this family member. Granzyme B in particular has been shown to be
necessary for effective CTL function; in its absence CTL mediated killing occurs at a
much slower rate (Heusel et al., 1994; Pardo et al., 2004). Granzyme B mediates
apoptosis through two mechanisms, one is through direct activation of caspase 3 (Adrain
et al., 2005; Cullen et al., 2005; Martin et al., 2007; Cullen et al 2008) and another is
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through the release of cytochrome C (Barry et al., 2000; Sutton et al., 2000; Almonti et
al., 2001).
The second important member of CTL-mediated destruction is the pore forming
protein, perforin. Perforin is also found in the granules of CTLs. Upon degranulation
perforin is released. It then inserts itself into the plasma membrane of the target cell, thus
forming a pore. In the absence of perforin there are major defects in CTL-mediated
killing by granzyme B (Kagi et al., 1994; Lowin et al., 1994). Thus granzyme and
perforin play dual roles in the destruction of target infected cells.

1.1.3 TH1 and CTLs in Autoimmunity
Autoimmune disorders such as multiple sclerosis, rheumatoid arthritis and
aplastic anemia have been associated with a TH1phenotype. In the context of autoimmune
disorders TH1 CD4+ T cells react to a self-peptide, resulting in systemic or tissue specific
targets. Once activated, TH1 cells produce an abundance of inflammatory cytokines such
as IL-2, TNF and IFN-γ. These cytokines lead the generation of additional, activated TH1
cells and also to the clonal expansion of the CD8+ T cells. TH1 cell are essential in
mediating the recruitment of CD8+ T cells, which then facilitate tissue destruction. The
presence of inflammatory cytokines create short lived effector CD8+ T cells (SLEC) that
mediate destruction and then die off, as opposed to becoming long lived memory CD8+
cells (Stemberger et al.,2007; Rubinstein et al.,2008; Obar et al., 2008). This pathway is
believed to mediate bone marrow destruction in the autoimmune disorder aplastic
anemia.
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1.2 Notch1 Signaling

1.2.1Notch Signaling Pathway

The Notch family of proteins was originally discovered in Drosophila in 1914,
and was given the name Notch after mutations in the gene led to a notched wing
phenotype. Since that time, Notch has been found to play a pivotal role in cell fate
decisions throughout many cellular events. There are four mammalian Notch receptors,
Notch 1-4, that are diagrammed in Figure 1.2. To activate Notch there and two families
of Notch ligands, Jagged (1, 2) and Delta-like (1, 3 & 4). The Notch receptor is a
transmembrane protein that undergoes a series of cleavage events to create its active form
(intracellular Notch). The first cleavage event of Notch occurs in the trans-golgi by a
network of furin-like convertases, which generate the mature heterodimer form of Notch
(Blaumueller et al., 1997; Logeat et al., 1998). In its processed, heterodimer form Notch
then translocates to the plasma membrane where its extracellular portion waits for
engagement with Notch ligands. Once a ligand binds to the extracellular portion of Notch
there is the second cleavage mediated by an ADAM metalloprotease, TNF-α-converting
enzyme (TACE), which releases the extracellular portion of Notch (Brou et al., 2000).
After the second cleavage a third site is exposed for the third and final cleavage by
gamma-secretase (De Strooper et al., 1999). Upon this final cleavage the active
intracellular portion of Notch is released from the cell membrane and translocates to the
nuclease. Notch signaling is outlined in Figure 1.3.
Notch initiates gene transcription by acting as a molecular switch to turn CSL
(CBF-1, SuH, Lag-1) from a transcriptional repressor to an activator. When CSL is
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activated it recruits co-activators, such as p300 and Mastermind-like-1, to regulate a
plethora of genes (Osborne and Minter, 2007). Additional studies have provided evidence
that Notch may also initiate gene transcription independently of CSL through a pathway
involving NF-κB (Osborne and Minter, 2007).

1.2.2 Notch1 and T Cells

Notch1 has been shown to be an important regulator of T cell development,
activation and differentiation. In the absence of Notch there is a skewed development of
B cells and abnormal thymic development (Radtke et al., 1999; Han et al., 2002). Notch
signaling was first implicated in T cell activation when it was discovered that
intracellular Notch1 was upregulated in T cells upon stimulation with anti-CD3 and antiCD28 antibodies (Palaga et al., 2003; Adler et al., 2003). Recently there has been a
number of studies that have shown Notch1 to be important in the development of TH1,
TH2, TH17 and Tregs (Minter et al., 2005; Fang et al., 2007; Amsen et al., 2007; Samon
et al.,2008; Keerthivasan et al., 2011 submitted). In polarized TH1 cells inhibition of
Notch resulted in decreased IFN-γ production. It was also shown that Notch was able to
decrease IFN-γ production in conjunction with NF-κB through its regulation of T-bet
(Minter et al., 2005, Shin et al., 2006). In addition to playing a role in TH1 polarization
Notch1 has also been named as a regulator of TH2 fate via Gata-3 and IL-4 production
(Fang et al.,2007; Amsen et al.,2007). However, additional studies have now
demonstrated that there is also Notch1-independent differentiation of TH2 cells, through a
β-catenin-mediated pathway (Yu et al., 2009). Data currently being revised for
publication has also suggested that TH17 cells require Notch1 for their differentiation,
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because in its absence there is decreased rorc (ROR-γt) transcription and decreased
production of IL-17 (Keerthivasan et al., 2011 submitted). Additionally, Notch1 was
shown to be necessary for the development of T regulatory cells through regulation of
Treg transcription factor foxp3 (Samon et al., 2008). Overall, these data support the
hypothesis that Notch1 regulates differentiation into many subtypes of T helper cells. The
many conflicting reports in the literature are most likely a result of the different methods
by which Notch signaling is abrogated. The distinction of how Notch1 chooses which
fate may be based on environmental factors such as cytokines, or perhaps the initiating
ligand and/or the signal strength which activates Notch1 that determines what subset
Notch1 will support in the race of T cell differentiation (Amsen et al., 2004).
Not surprisingly studies have also found Notch1 signaling to be important in the
development and activation of CD8+ T cells. Notch1 was shown to be a regulator of the
transcription factor eomesodermin (Eomes), which is responsible for the expression of
granzyme B and perforin, shown in Figure 1.1. Eomes is a member of the T-box family
of transcription factors and is similar to T-bet. Inhibition of Notch1 through
pharmacological or genetic (Notch1 antisense mice) approaches resulted in decreased
expression of Eomes and, subsequently, decreased granzyme B and perforin production
(Cho et al. 2009). This study also showed that inhibiting Notch1 led to decreased CTL
function in an OVA-specific model. Additionally, Notch1 activation was shown to be
necessary for the expression of T-bet (Minter et al., 2005). T bet has been shown to
mediate the production of SLECs (Joshi et al., 2007; Intlekoler et al., 2007), which are
essential in cell-mediated tissue destruction. During viral infections this population of
CD8+ T cells rapidly expands and then involutes after viral clearance. During a viral
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response these cells possesses lytic capabilities, tissue migration, but limited self-renewal
and decreased lifespan. This population differs from memory precursor effector T cells
(MPEC); which have increased self-renewal capabilities and are vital during secondary
infection. Altogether these data show that Notch1 signaling plays a critical role in the
development of several T helper cell subsets and effector T cells.

1.2.3 Gamma Secretase Inhibitors

The third cleavage event in the Notch signaling pathway is mediated by gammasecretase (De Strooper et al., 2000), Figure 1.3. The gamma secretase complex is made
up of four proteins presenillin1/2, APH1, Pen2 and nicastrin. All four of these proteins
need to be present in order for the complex to have proteolytic capabilities (Edbauer et
al., 2003; Kimberly et al., 2003; Takasugi et al.2003). Gamma-secretase was shown to
regulate intramembrane proteolysis of the amyloid precursor protein (APP) (Haass and
Selkoe, 1993) In addition to APP gamma-secretase mediates the cleavage of E-cadherin,
CD44, Notch and other type-one proteins. Gamma-secretase inhibitors (GSI) were
created to prevent the subsequent activation of Notch and other known targets. There are
several types of GSIs that act either through molecular mimicry or as competitive
inhibitors. Although gamma-secretase may mediate the cleavage of several proteins in the
immune system, Notch is believed to be its main target in T cells. GSIs are approved in
for use in clinic trials and are currently being used in the treatment of Alzheimer and
several types of cancer including, prostate, breast, pancreatic and lung cancer, melanoma
and T cell acute lymphoblastic leukemia (http://clinicaltrials.gov/, 2011).
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1.3 PKC-θ: Regulator of T Cell Life and Death

1.3.1 Protein Kinase C

Protein Kinase Cs are a subfamily of kinases which specifically phosphorylate
serine and threonine residues. This kinase family has been found to have non-redundant
roles in T cell biology. The family of 10 isozymes is divided into three groups based
upon their mode of activation. Conventional PKC family members are activated by
calcium and a second message from diacylglycerol (DAG), this subfamily consists of
PKC-α,-β and -γ. PKC-ζ is a member of the novel PKC family which is not dependent on
calcium; this subfamily also includes PKC-ε,-δ and -ε. The last subfamily contains the
atypical PKCs which are not activated by calcium or DAG, this includes PKC-δ and -λ.
PKC-ζ shares a similar structural configuration with other novel members. This
includes an NH2 terminus, C2-like domain, pseudosubstrate (PS), DAG binding domain
(C1), unique V3, and kinase domain. In the C2 domain there is a tyrosine residue which
is phosphorylated by Lck during T cell activation (Liu et al., 2000). The PS domain binds
to the kinase domain which keeps PKC-ζ in an inactive state. In response to DAG, which
is generated downstream of PLCγ1 signaling PKC-ζ undergoes a conformational change
into an active state whereby it can then activate its substrates. PKC-ζ structure is
diagrammed in Figure 1.4. The exact mechanism of these changes is not completely
understood, but it is hypothesized that phosphorylation of tyrosine by Lck is necessary.
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1.3.2 PKC-θ in T cell Activation
Data in the literature have shown PKC-ζ to be expressed predominantly in T cells,
muscle cells and platelets. Due to its specific expression and its essential role in T cell
activation it is an attractive target for therapeutics to dampen immune responses. PKC-ζ
in T cell signaling is outlined in Figure 1.5. Although there are other PKC members
expressed in T cells, PKC-ζ differs from them because of its location and rapid
recruitment to immunological synapse (IS) upon T cell stimulation (Bi et al., 2001;
Burack et al., 2002). The IS is the interface between the APC and the T cell during
activation. In order for the IS to form there are a series of conformational changes that
must occur at the cell membrane (Grakoui et al., 1999). In the absence of PKC-ζ the IS
cannot be formed, thus there is no sustained T cell activation (Valitutti et al., 1995). Part
of the IS involves the recruitment of the CBM complex, which is made up of the
scaffolding protein Carma1 together with Bcl10 and MALT-1 (Thome et al., 2007).
PKC-ζ has been shown to positively regulate the activation of NF-κB through the
formation of the CBM complex. Without this signaling cascade there is no transcription
the il2 gene, Figure 1.5.
In order to truly understand what an integral role PKC-ζ plays in T cell
development the creation of a knockout mouse was of utmost importance. PKC-ζ
knockout mice were generated by inactivating the PKC-ζ gene by homologous
recombination in embryonic stem cells. Within the gene, the ATP-binding site of the
kinase domain was replaced with a neomycin cassette. Disruption of the gene resulted in
the abrogation of PKC-ζ protein production. The loss of PKC-ζ had no effect on the
development of immature T cells, but there were serious defects in mature T cell
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responses. PKC-ζ-deficient cells had insufficient signaling through NF-AT, AP-1 and
NF-κB, upon stimulation (Sun et al., 2000). The disruption in signaling cascades also led
to impaired IL-2 production and reduced expression of the IL-2 receptor. This defect
eventually results in apoptosis. Supplying exogenous IL-2 to stimulated T cells was able
to partially overcome activation defects and prolong the cells’ survival, but not their
proliferation (Sun et al., 2000; Manicassamy et al., 2006). PKC-ζ is needed to
antagonize apoptotic signals like BAD (Bertolotto et al., 2000; Villalba et al., 2001)
Without PKC-ζ, T cells also fail to upregulate the anti-apoptotic signals, Bcl-2 and BclxL, which results in accelerated apoptosis during T cell stimulation, compared to wild
type cells (Manicassamy et al., 2006). PKC-ζ knockout mice show normal TH1 responses
to viral infections, but showed defective TH2 responses (Giannoni et al.,2006; Marsland
et al., 2004; Salek-Ardakani et al., 2004; Mowen and Glimcher, 2004; Salek-Ardakani
et al., 2005; Stevens et al., 2006). PKC-ζ knockout mice have been shown to have
decreased disease severity or no development of disease in autoimmune models of EAE,
allergic asthma, experimental colitis and type II collagen-induced arthritis (SalekArdakani et al., 2005; Tan et al., 2006; Salek-Ardakani et al., 2004; Nagahama et al.,
2008; Healy et al., 2006). These studies highlight the potential benefit of using PKC-ζ
inhibitors in the treatment of autoimmune disorders.

1.3.3 Rottlerin is an Inhibitor of PKC-θ

Rottlerin (mallotoxin) is a kinase inhibitor that was isolated from Mallotus
philippomesis, which is also known as the monkey-face tree. Rottlerin was originally
discovered as an inhibitor of members of the novel family of protein kinases C,
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specifically PKC-δ (Gschwendt et al., 1994). Since then, additionally studies have
revealed that rottlerin is in fact not an effective inhibitor of PKC-δ, but is an inhibitor of
PKC-ζ (Soltoff, 2007) and other kinases such as CaMIII kinase. Rottlerin is believed to
inhibit PKC-ζ by competing for the ATP binding site (Gschwendt et al., 1994), this in
turn prevents its kinase activity and in turn phosphorylation of its substrates, such as
Carma1 (Sommer et al., 2005; Matsumoto et al., 2005). Human T cells (CD4 and CD8)
stimulated in the presence of rottlerin show decreased proliferation, which is attributed to
decreased IL-2 production and CD25 (IL-2 receptor) expression. Addition of IL-2 to
stimulated cultures was not able to restore the proliferation of T cells (Springael et al.,
2006). Additionally, rottlerin was shown to inhibit the development of TH1cells by
decreasing T-bet expression and IFN-γ production (Solomou et al., 2006). Unlike PKC-ζ
knockout mice, treatment with rottlerin did not affect calcium mobilization during T cell
activation (Springael et al., 2006). From these studies it would appear that rottlerin, or
other PKC-ζ inhibitors would be excellent candidates for treating autoimmune disorders
by inhibiting T cell activation and inducing cell death.

1.4 Notch1 and PKC-θ: Friends of T Cell Activation

1.4.1 Notch1 and PKC-θ Interact
The exact relationship between Notch1 and PKC-ζ remains unknown; however,
we do know that the absence of either protein results in decreased activation of the other
(Osborne & Minter unpublished data). Using immunofluorescence microscopy Notch1
and PKC-ζ were found to co-localize at the immunological synapse at the time of T cell
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activation (L. Minter, unpublished data). Additionally, it was discovered that the two
proteins could be immunoprecipated together as part of the CBM complex (Shin et al., in
preparation).

1.4.2 Notch1 and PKC-θ both Regulate NF-κB Activity
The NF-κB signaling pathway regulates the transcription of many downstream
genes. One of the most-recognized in T cell activation is il2. Both Notch1 and PKC-ζ
have been shown to directly mediate the activation of NF-κB. The potential mechanisms
that allow cross-talk between Notch1 and PKC-ζ are diagrammed in Figure 1.6. NF-κB is
sequestered in an inactive state in the cytoplasm by IκB. IκB must be degraded to free
NF-κB and allow it to enter the nucleus. The IKK (IκB kinase) complex mediates the
degradation of IκB and subsequent activation of NF-κB. The IKK complex becomes
activated in response to T cell stimulation and inflammatory cytokines (Beinke, 2004).
NF-κB is regulated in a negative feedback loop since its activation leads to subsequent
transcription of IκBα. Once synthesized, IκBα can translocate into to the nucleus to
sequester NF-κB back to the cytoplasm and once again prevent its activation (ArenzanaSeisdedos et al., 1997; Rodriguez et al., 1999; Hoffmann et al., 2002; Nelson et al.,
2004).
The formation of the CBM complex requires both Notch and PKC-ζ. PKC-ζ is
rapidly recruited to the immunological synapses after T cell activation; it then recruits
Carma1, Bcl10, and MALT-1. Notch has also been shown to bind with Carma1, as part
of the CBM complex. The assembly of this complex leads to the activation of IKK and
degradation of IκB, allowing the activation of NF-κB. Notch also has been shown to have
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an additional role in maintaining NF-κB in the nucleus by competing for IκBα binding to
the subunit p50, thus retaining NF-κB subunits in the nucleus (Shin et al., 2006).
Although the exact mechanism of how Notch and PKC-ζ act on one another is unknown
they both appear to have essential functions in the same pathways, as outlined in Figure
1.6.

1.5 Immune Mediated Bone Marrow Failure Syndromes: An Autoimmune Disorder

1.5.1 Aplastic Anemia

Immune-mediated bone marrow failure syndromes develop as a result of the loss
of self-tolerance in the T cell compartment or genetic mutations. Autoreactive T cells
mediate the destruction of one or all progenitor cells that are responsible for making the
components of the blood. Some examples of immune-mediate bone marrow failure
include Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria and Myelodysplasia.
Aplastic Anemia (AA) is a rare disease with only 900 new cases diagnosed each year in
the United States. Age distribution of patients diagnosed with AA fall into two groups
15-25 years and over 60 year. AA is known as a disease of the young, since most cases
are found in the younger group (Scheinberg et al., 2008). AA develops following the loss
of self-tolerance and the expansion autoreactive T cells, which infiltrate and destroy the
bone marrow. The antigen which triggers this response remains unknown. Currently,
there have been some autoantibodies that have been identified in AA patients. Kinectin is
a widely expressed protein, to which autoantibodies have been found in approximately
40% of patients. Another autoantibody which was found in a much smaller subset of
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patients is diazepam-binding related protein-1, an enzyme that regulates the oxidation of
unsaturated fatty acids (Young et al., 2006). The relevance of these autoantibodies to
disease is still unclear. T cell-mediated destruction of stem and progenitor cells results in
hypocellular bone marrow (BM). The consequence of a hypocellular BM is the inability
to replenish the components of the blood, resulting in peripheral pancytopenia.
Subsequently deficiency in platelets, red and white blood cells leads to an increased risk
of bleeding and infection in AA patients.

1.5.1 T Cell-Mediated Destruction
Autoreactive CD4+ and CD8+ T cells mediate the destruction of stem and
progenitor cells through three different mechanisms. The first documented mechanism
that leads to destruction in the BM is direct killing by CD8+ T cells. Cytotoxic CD8+ T
cells mediate the destruction through the actions of perforin and granzyme B. Perforin is
a pore forming protein, which binds to the target cell and allows the entrance of
granzyme B, which mediates target cell death. Both perforin and granzyme B are
increased in patient with AA (Xu et al., 2003; Franzke et al., 2006). Another welldocumented mechanism of death mediated by T cells is Fas/Fas lignad interaction
(Maciejewski et al., 1995; Callera et al., 1998; Ismail et al., 2001). T cells upregulate Fas
ligand and induce cell death through Fas receptor expressed on the stem and progenitor
cells. The third mechanism of death is through increased inflammatory cytokine
production by the infiltrating T cells. Hematopoietic stem cells (HSC) exposed to the
cytokines IFN-γ and TNF undergo apoptosis through bystander cell death (Maciejewski
et al., 1995; Selleri et al., 1996; Young et al., 2006; Bacigalupo, 2007). The increased
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levels of cytokines secreted by the infiltrating T cells also inhibit the HSCs’ and
progenitor cells’ ability to proliferate. These mechanisms by which T cells induce death
in the HSCs and progenitor cells are outlined in Figure 1.7.

1.5.3 Aplastic Anemia is a TH1-Mediated Disease
Some cases of Aplastic Anemia develop from the chemical exposure, pregnancy
or other conditions that can be traced to an initiating event. However, the majority of
cases of AA are idiopathic. The clinical observation that AA patients respond to
immunosuppressive therapy is the most concrete evidence that AA is an autoimmune
disorder (Young et al., 2006). Analyses of T cells from AA patients have demonstrated
that AA is a TH1-mediated autoimmune disorder. This conclusion was made based on the
observation that T cells from patients had increased production of TH1 hallmark
cytokines, IFN-γ, TNF-α and IL-2 (Zombous et al.,1984;Young et al., 1987; Zombous et
al., 1985; Sloand et al., 2002; Giannakoulas et al., 2004; Young et al., 2006; Bacigalupo,
2007). CD4+ T cells from patients have increased expression of T-bet (tbx21), the
transcriptional master regulator of TH1 cells (Solomou et al., 2006). Increased protein
expression of T-bet in patients with AA correlated with increased levels of IFN-γ and IL12 receptor expression (Solomou et al., 2006). Based on this evidence AA is believed to
be a TH1-mediated disease.

1.5.4 Current Treatment for Aplastic Anemia

When treating Aplastic Anemia patients there are three levels of care: supportive
treatments, immunosuppressive treatment (IST) and bone marrow transplants (BMT).
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BMT is the first choice of treatment, but many factors can affect the outcome, first and
foremost is the availability of a HLA-matched donor. Siblings are the best candidates, but
matches can sometimes be found through a bone marrow donor registry. Children are
better candidates for bone marrow transplant than adults, because they are less likely to
have complications from graft-versus-host (GVH) disease and show better overall
survival (Scheinberg et al., 2008). BMT is a superior form of treatment; however, in
many cases a matched donor is not available within the necessary time frame. While
waiting for a donor match patients will receive a standard IST regimen. The current
protocol for IST is antithymocyte globulin (ATG) and Cyclosporine (CsA) (Scheinberg et
al., 2008). ATG treatment relieves disease symptoms by killing off the T cells that are
mediating the destruction of the bone marrow. ATG is administered intravenously for 812 hours for four days, although these regimens vary between hospitals. CsA inhibits the
autoreactive T cells ability to become activated; CsA is administered orally in either
liquid or a pill. The dosing of CsA is dependent on the patient’s weight since a certain
concentration is essential to maintain bioactivity of CsA, but also minimize side effects.
When used alone ATG has the ability to improve blood count only about half the time,
but when used with CsA approximately 70% of patients respond to treatment. Full
benefits from the treatment can take up to 9 months. After that period of time 30% of
patients will relapse and will need another course of treatment.

1.6 Significance and Hypothesis

Current treatments for Aplastic Anemia are limited due to the available
information about the antigen which causes the development of autoreactive T cells and
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the subsequent destruction of the bone marrow. Immunosuppressive therapies provide
rescue of disease symptoms, but some patients do not respond to the treatments currently
available. The aim of these studies are as follows: i) to create a murine model that
recapitulates AA symptoms; ii) to use this model to identify novel molecules that are
important in the pathogenesis of disease; iii) to discover therapeutics to inhibit these
novel molecules. Using our murine model of bone marrow failure we sought to evaluate
the role of two key players in T cell differentiation and activation, Notch1 and PKC-ζ.
Our hypothesis is that both Notch1 and PKC-ζ play important roles in disease initiation
in a urine model of BMF syndrome. These targets regulate the activation and
polarization of a CD4+ T cell towards a TH1 phenotype. They also play an important role
in the maturation and activation of effector CD8+ T cells. Therefore, we believe that
inhibiting Notch1 and PKC-ζ should result in decreased disease severity in mice induced
with Aplastic Anemia. Our hypothesis and disease mechanism are outlined in Figure 1.8.
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Figure 1.1. T-cell Subsets
A schematic that outlines the different CD4+ and CD8+ T cell subsets, including their
required transcription factors and signature cytokines.
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Figure 1.1. Notch Receptors
There are four mammalian Notch receptors. The extracellular portion of all four contains
epidermal growth-factor-like repeats, which bind to signaling ligands Jagged (1&2) or
Delta-like (1, 3&4). There are three LIN repeats. The intracellular portion contains a
RAM domain (RBP-J-associated molecule) that binds CSL and 7 Ankyrin repeats that are
used for protein binding including CSL and NF-κB. At either end of the Ankyrin repeats
there are nuclear localization signals, two for Notch 1-3 and one for Notch 4. The
transcriptional activation domain activates downstream targets; there is no TAD domain
in Notch 3 or 4. The PEST (C-terminal Pro Glu Ser Thr) domain regulates degradation of
Notch proteins.
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Figure 1.2. Notch Signaling
After engagement with one of its ligands (Jagged 1, 2; Delta-like 1, 3 &4), Notch
undergoes cleavage events mediated through TACE and gamma-secretase, as designated
by the lighting symbol. Notch then translocates to the nucleus where it binds to CSL to
activate downstream targets

23

Figure 1.3. PKC-θ Structure
A diagram showing the domains that makes up PKC-ζ. The C2 domain contains the
tyrosine residue that is phosphorylated by Lck during T cell activation. The PS domain
binds to the kinase domain to keep it in an inactivated state. C1 is the binding domain for
DAG and allows for the conformation change in PKC-ζ to an active form.
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Figure 1.4. T Cell Signaling Cascade
After engagement of the T cell receptor and CD28 there are a series of phosphorylation
events that ultimately lead to the recruitment of PKC-ζ to the immunological synapse as
shown here. PKC-ζ phosphorylation leads to the activation of IKK complex which
degrades IκB complex and subsequently releases NF-κB. NF-κB then regulates the
transcription of il2.
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Figure 1.5. Notch and PKC-θ in NF-κB Activation
Notch1 can act as a scaffolding protein during the formation of the CBM complex along
with PKC-ζ. Additionally, Notch1 can maintain nuclear retention of NF-κB.

26

Figure 1.6. Three Mechanisms Result in Death of HSCs and Progenitor Cells
T cell mediated destruction through three documented mechanisms. 1) The direct killing
by CTLs through granzyme B/perforin. 2) The upregulation of Fas ligand on T cells and
Fas receptor expression on HSCs and progenitor cells. 3) The production of inflammatory
cytokines, IFN-γ and TNF-α, which not only kill the HSCs and progenitor cells, but also
severely inhibit their proliferation capabilities.
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Figure 1.7. An Overview of Mechanisms Leading to Bone Marrow Destruction.
Bone marrow damage in Aplastic Anemia develops from the initial activation of CD4+
TH1 cells. Notch1 and PKC-ζ signals activate CD4+ T cells and subsequently activate
NF-κB and Tbet. We can inhibit signaling through Notch and PKC-ζ with GSI or
Rottlerin, respectively. In the absence of the inhibitors, activation of TH1 cells results in
the clonal expansion of CD8+ T cells and the production of inflammatory cytokines.
These mechanisms then lead to death of the stem and progenitor cells. (Adapted from NS
Young, 2006.)
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CHAPTER 2
DEVELOPMENT AND CHARACTERIZATION OF APLASTIC ANEMIA
MURINE MODEL

2.1 Introduction

The antigen which initiates Aplastic Anemia remains unknown; therefore, there is
no true autoimmune model of AA. To recapitulate AA using animal models, researchers
use acute graft-versus-host disease models (GVHD). These types of GVHD models are
induced by the infusion of major or minor histocompatibility-mismatched leukocytes into
an F1 progeny (Shlomchik, 2007). These GVHD models develop disease symptoms that
are similar to those observed in patients with AA. Disease-induced mice have T cell
infiltration into the bone marrow, where they mediate the destruction of stem and
progenitor cells. The loss of stem and progenitor cells leads to hypocellular bone marrow
and peripheral pancytopenia (Mori et al., 1998; Bloom et al., 2004). These models
recapitulate disease symptoms accurately, and the current treatment using cyclosporine A
and anti-thymocyte globulin has been validated using a GVHD model (Bloom et al.,
2004).
The model which we generated was developed using a combination of two
previously published protocols used to induce BMF. From the first protocol, we used the
same MHC mismatch of H2b cells in to an H2b x H2d F1 progeny, although we used a
different mouse sub-strain of Balb/c (Bloom et al., 2004). To create this AA model we
also used a previously reported method of using bulk splenocytes as the initiating cell
source (Mori et al., 1998). Preliminary data from our lab (Emily Roberts, unpublished
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observations) showed that we were able to induce disease with intraperitoneal (IP)
injections of bulk splenocytes, just as effectively as intravenous (IV) injections. In fact
we were able to produce more consistent results with the IP injections compared to the IV
injections, most likely due to the technical ease of IP injections.
Generation of F1 hybrids is achieved by crossing a Balb/c (H2b) female with a
C57BL/6 (H2d) male. These F1 hybrids have a major histocompatibility complex of
H2b/d, as outlined in Figure 2.1.Then an IP infusion of C57BL/6 splenocytes is used to
induce disease after light irradiation (3Gy). Initial experiments were performed to
determine the necessary cell number to induce disease. In the literature there are several
reports of different models of GHVD. Some studies have demonstrated that the initiating
T helper subtype will dictate an organ specific GVHD (Yi et al., 2009). While
establishing the model we did not observe any special phenotype based on T cell subsets,
but what was discovered was the importance of the number of cell to induce disease.
Using a lesser number of total splenocytes (3x107) resulted in a lethal GVHD response
which caused mice to succumb to disease on average at day 14 with no signs of bone
marrow destruction. Interestingly, mice which received more splenocytes (5x107)
survived longer periods of time (18-26 days). Mice who succumbed to disease at earlier
time points showed a GVH response that was directed towards the gut, while mice that
were induced with a greater number of splenocytes induced destruction mediated towards
the bone marrow. Once we determined that 5x107 splenocytes provided reproducible
disease symptoms, we used that number to characterize this AA model. Our induction
protocol and disease time course is outlined in Figure 2.1, with an in-depth description
provided in the Materials and Methods.
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2.2 Results

2.2.1 Murine Model of AA Recapitulates Human Pathology

Once patients are diagnosed with aplastic anemia there is already destruction of
the bone marrow cavity. Usually patients are diagnosed once they have developed
complications from peripheral pancytopenia. Once patients present with symptoms of AA
a bone marrow aspiration is performed to confirm diagnosis. When sacrificed on day 17,
mice induced with AA showed a dramatic decrease in the number of cells present in the
bone marrow cavity as determined by trypan blue counts, compared to irradiation
controls (Figure 2.2 A). We also evaluated cellularity in the sternums of irradiation
controls and AA-induced mice. Sternums were fixed, paraffin-embedded and then H&E
stained. As expected, disease-induced mice had an extensive loss of cellularity compared
to un-induced control mice Figure 2.2 B. Peripheral blood was harvested from animals
using cardiac puncture and complete blood counts (CBC) were obtained by running
samples through a veterinary hematology analyzer. White and red blood cells where
significantly reduced in diseased mice (Figure 2.2 C & D). Patients with AA experience
cachexia, a chronic wasting which is associated with dramatic weight loss. At the time of
harvest mice induced with disease presented with decreased activity, shallow breathing,
unkempt coat and robust weight losses based on a percent weight change, Figure 2.2 E.
As with patients, we also observed increased circulating levels of inflammatory
cytokines. Using a cytometric bead array we were able to quantify the amount of
circulating IFN- γ and TNF in mice with AA, whereas little to no cytokines were present
in our irradiation controls (Figure 2.2 F). Although IL-2 and IL-17 (Gu et al., 2007) have
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been found at increased levels in patients with AA, we saw no increases in the levels of
either cytokine in AA mice.

2.2.2 Disease is Mediated by Donor T cells that Infiltrate into the Bone Marrow

Although there is a small resident population of mature T cell in the bone marrow,
a major infiltration of them is not typical. Patients with AA have a massive infiltration of
T cells into the bone marrow cavity that wreaks havoc on the sensitive microenvironment
and leads to the death of stem and progenitor cells. AA mice have massive infiltration of
T cells into the bone marrow cavity as evaluated by flow cytometric analysis (Figure
2.3A). To distinguish between donor and host T cells we used C57BL/6 GFP+ mice as the
lymphocyte donors. Using this approach allowed us to track and monitor the location and
expansion of donor T cells. In the bone marrow the vast majority of infiltrating CD4+ and
CD8+ T cells was donor-derived (Figure 2.3 B). Additionally we saw expansion of T
cells, over the disease time course, in the lymph nodes, spleen and peripheral blood of
induced mice (Figure 4.3).

2.2.3 Genes that are Dysregulated in Aplastic Anemia Patients are also Dysregulated
in Our Mouse Model

To determine whether AA mice truly recapitulate the mechanisms that mediate
disease symptoms in patients with AA, we isolated T cells from the spleen and BM of
AA mice. Using q-PCR when then evaluated several genes that were found to be
dysregulated in AA patients. Using positive selection, CD4+ and CD8+ T cells were
isolated from AA mice and irradiation controls. Due to the small number of T cells in AA
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mice, 3-6 mice per cohort were pooled and RNA was isolated. cDNA was prepared and
analyzed using SYBR green qRT-PCR. Gene expression was evaluated by relative
expression and was analyzed using the delta,delta CT method. Target genes were
normalized to β-actin and relative expression was based on T cells isolated from an
irradiated control. Using qRT-PCR we found similar gene dysregulation in AA mice that
have also been documented in AA patients (Franzke et al., 2006; Solomou et al., 2006).
We observed increased transcript levels of the following genes: ifng, tnf, prf-1, gzmb,
tbox21, il12rb2 and a decrease in pf4 expression, Figure 2.4 A-G.

2.3 Discussion

Although there are limits to using animal models for research they are a
tremendous resource. They have led to the discovery of novel molecules, mechanisms,
cell types and therapeutics that have been found to be relevant in the diagnosis and
treatments of a variety of human diseases. This mouse model of AA is another excellent
resource for studying T cell activation, polarization and T-cell-mediated destruction of
stem and progenitor cells in the bone marrow. This model faithfully replicates the disease
symptoms and characteristic of AA in humans, Figures 2.2 and 2.3. In addition to this, T
cells isolated from AA mice have a transcriptional phenotype similar to T cells isolated
for patients with AA, Figure 2.4.
The extensive characterization of this model shows that although it is technically
a GVHD model, it recapitulates the symptoms and gene dysregulation seen in humans
with AA. We presume there must be pathways in both responses that function in
relatively similar ways which lead to identical outcomes in AA patients and in AA mice
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(T cell-mediated destruction of the BM). Thus this model of AA provides a suitable
source with which to ask questions about T cell activation, polarization and mechanisms
of disease progression.
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Figure 2.1. AA Disease Induction and Time Course
A schematic outlining generation of F1 progeny and disease induction (A). Time line for
disease induction through time of harvest (B).
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Figure 2.2. AA Induced Mice Show Disease Symptoms Similar to AA Patients
Mice were harvested 17 days after disease induction. Bone marrow cells were flushed
and leukocytes were counted using trypan blue staining (A). Cellularity was also
evaluated in the sternum with paraffin- embedded sections stained with H&E (B).
Peripheral pancytopenia was evaluated by peripheral blood values using a hematology
analyzer which provides white and red blood cell counts (C, D). To determine percent
weight change, mouse weights were recorded on the day of disease induction and day of
harvest (E). Circulating cytokine levels were quantified by flow cytometry using a
cytometric bead assay to detect IFN-γ and TNF (F) in the plasma from the peripheral
blood.
*P<0.05, **P<0.01, ***P<0.001
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Figure 2.3. Mice Induced with AA have Infiltrating T Cells that are Donor Derived
After flushing the bone marrow cells they were stained for CD4 and CD8 and analyzed
by flow cytometry (A); each plot represents one animal. Using FACS analysis we also
quantified the percent of BM infiltrating CD4 and CD8 T cells that were GFP-positive
(B).
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Figure 2.4. Gene Dysregulation Seen in Patients with AA is Recapitulated in AA
Mice
qRT-PCR analysis of gene expression in T cells isolated from BM of spleen of AA mice
compared to T cells isolated from the spleen of an irradiation controls. Values for each
gene were normalized to β-actin and relative expression was determined by normalizing
to CT values from irradiation controls. Transcripts shown to be up regulated in patients
with AA correlated well with transcripts upregulated in AA mice: IFN-γ (A), TNF (B),
perforin (C), granzyme B (D), T-bet (E), and IL-12Rβ2 (F). Similar to patients with AA
platelet factor 4 was down regulated in AA mice (G).
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CHAPTER 3
NOTCH1 PLAYS A ROLE IN THE DISEASE PROGRESSION IN APLASTIC
ANEMIA MICE

3.1 Introduction

Notch1 has been shown to be essential for the polarization of T cells toward a TH1
phenotype (Minter et al., 2005). Therefore we hypothesized that Notch1 was involved in
AA, which is believed to be a TH1-mediated disease (Zombous et al., 1984; Young et al.,
1987; Zombous et al., 1985; Sloand et al., 2002; Giannakoulas et al., 2004; Young et al.,
2006; Bacigalupo, 2007). To address if Notch1 played a role in disease progression, we
investigated Notch1 activation in AA induced mice.
In order to determine if Notch1 was an important protein in disease onset, we
used two approaches to abrogate Notch1. First, we targeted Notch1 genetically using
conditional Notch1 knockout mice. These Notch1-floxed mice were then crossed to an
Mx-Cre expressing strain. Notch1 was deleted in peripheral T cells following a course of
polyinosinic: polycytidylic acid (poly IC) administration. Our second method to target
Notch1 activation was using a gamma-secretase inhibitor (LY411, 575). GSI prevents the
third and final cleavage of Notch1 and this cleavage is necessary to release the active
portion of Notch1. In addition to asking if Notch1 is essential in disease progression,
additional studies were done to validate GSI as a possible therapeutic to treat Aplastic
Anemia.
In an effort to establish GSI as a possible therapeutic we also wanted to evaluate
its effect on hematopoiesis. Notch has been found to be important in many cell fate
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decisions including hematopoiesis. To ensure that GSI had no ill effects on hematopoiesis
we performed a series of long-term treatment studies consisting of reconstitution assays.
These studies are essential in validating GSI as a possible therapeutic for AA.

3.2 Results

3.2.1 Notch1 is Upregulated in T Cells of AA Induced Mice

When T cells become stimulated and polarized there is an increase in the amount
of active intracellular Notch1 that can be detected (Palaga et al., 2003; Adler et al.,
2003). Therefore, we wanted to determine if Notch1 was activated in the T cells of AA
induced mice. Using intracellular staining and flow cytometry, the expression of the
intracellular portion of Notch1, N1ic, was determined by mean florescence intensity
(MFI). Compared to splenic T cells of irradiated controls, we observed increased N1ic in
T cells that were isolated from both the spleen and BM of AA induced mice (Figure 3.1
A). Upon closer analysis we observed that there was a significant upregulation of N1ic in
CD4+ T cells and only a modest increase in CD8+ T cells, Figure 3.1 B. Furthermore,
there was an increase in notch1 transcripts in T cells isolated from the spleen and BM of
AA mice, compared to splenic T cells from irradiation controls, Figure 3.2 A. T cells
isolated from AA mice were also evaluated for their expression of other Notch family
members. No robust difference was detected in the amount of notch2 expression. We
observed only a slight increase in the expression of notch3 in T cells from AA mice
(Figure 3.2 B&C). There was also a marked increase in the amount of rbpj (also known
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as CSL) transcript in T cells isolated from the spleens of AA-induced mice, Figure 3.2
(D).

3.2.2 Conditional Notch1 Knock Out Mice

To validate the role of Notch1 in our model, we used Notch1 conditional
knockout mice (N1KO). N1KO transgenic mice were created using floxP sites on either
side of the notch1 gene (Yang et al., 2004). N1KO mice were crossed with MxCre mice,
and were bred back to homozygosity for the N1 transgene, N1KOfl/flMxCre+/-. Notch1
was floxed, in vivo, with PolyIC treatment. MxCre floxing has been shown to target gene
deletion in the liver, spleen, bone marrow and thymus (Kuhn et al., 1995). As outlined in
the schematic, Figure 3.3A, N1KOfl/flMxCre+/- (N1KO) mice received five intraperitoneal
(IP) injections of PolyIC every other day and then rested for three weeks. To control both
for the leakiness of the Cre and treatment with PolyIC, we used N1KOfl/flMxCre+/-mice
untreated (without Poly IC treatment, Cre controls) and N1KOfl/flMxCre-/- mice treated
with Poly IC (Poly IC controls).
To validate the deletion of Notch1 after PolyIC treatment, CD4+ and CD8+ splenic
T cells were isolated and stimulated with plate-bound anti-CD3 and anti-CD28 for 24
hours for qRT-PCR analyses, and for 48 hours for protein expression by flow cytometry.
N1KO mice had significantly less notch1 expression by qRT-PCR compared to T cells
isolated from Cre and PolyIC controls. N1KO mice also had considerably less expression
of N1ic as determined by intracellular staining both of CD4+ and CD8+ T cell subsets,
Figure 3.3 B&C. To ensure that N1KO mice had comparable percentages of T cell
subsets in the spleen, we also evaluated total percentages of CD4+ and CD8+ T cell in the
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spleens of these mice. Both CD4+ and CD8+ cell percentages were normal and did not
differ from control mice, Figure 3.3 D. After this validation N1KO mice were used as
splenocyte donors to induce disease in F1 recipients.

3.2.3 Notch1 Plays a Role in Disease Severity

F1 hybrid mice were induced with bulk splenocytes from N1KO, Cre or PolyIC
control animals. Mice that received N1KO splenocytes showed decreased disease
severity compared to mice induced with bulk splenocytes from Cre or PolyIC control
mice. N1KO induced animals had significantly higher BM cellularities compared to
either control group of induced mice (Figure 3.4 A). Although the values do not reach
significance, we observed trends that mice receiving N1KO splenocytes had decreased
weight loss and less peripheral pancytopenia compared to both control groups (Figure 3.4
B-D). Plasma was collected from all three groups of induced mice and the levels of INF-γ
and TNF were quantified by CBA. CBA analysis revealed that there were no significant
differences in the circulating levels of IFN-γ or TNF, as shown in Figure 3.4 E&F.
BM and splenic T cells from AA induced mice were stained for CD4+, CD8+ and
N1ic; N1KO-derived T cell had reduced capability to infiltrate the BM cavity of F1
progeny compared to either control (Figure 3.5 A). N1ic levels were also decreased in the
F1 recipients that receive N1KO splenocytes, as evaluated by MFI (Figure 3.5 B).
Additionally mice that received N1KO splenocytes were able to survive longer than
control induced mice (Figure 3.5C). In these experiments induced mice were monitored
daily as disease developed and were sacrificed when they were determined to be
moribund, unable to take food and water. N1KO mice had a (median) survival time of 25
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days, Cre controls 21 days and Poly IC controls 19 days. Although not significant this
data still strongly suggests that Notch1 plays a role in the disease progression of AA
induced mice.

3.2.4 Inhibition of Notch with a Gamma-Secretase Inhibitor Results in Disease
Rescue

Gamma-secretase has many different targets; one of the most prominent targets in
the immune system is believed to be Notch. Since we determined that Notch1 is
important in disease progression, we hypothesized that treating mice with a gammasecretase inhibitor (GSI) should also result in disease rescue. GSI (LY 411,575) was
delivered to mice using two routes of administration: orally, in rodent chow and
intraperitoneally, dissolved in DMSO. Preliminary studies were done employing a
pretreatment regimen with GSI chow beginning two weeks before disease induction or
with IP injections beginning three days pre-induction.Validation of GSI chow
pretreatment, showed that mice fed GSI chow for two weeks had T cells that expressed
less intracellular Notch1 than mice fed control chow. N1ic levels were determined
following ex vivo stimulation with anti-CD3 and anti-CD28 for 24 hours (Figure 3.6).
Once GSI was validated we began pretreatment studies in which mice received
one of the following treatments, daily: i) the GSI (chow or IP) at 5mg/kg, ii) control
chow, or iii) DMSO vehicle control. As expected, mice receiving either GSI treatment
had increased bone marrow cellularity and less weight loss, compared to control-treated
mice (Figure 3.7 A&B). CBC analysis revealed that GSI-treated animals had significantly
higher levels of circulating white and red blood cells with both routes of administration
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(Figure 3.7 C&D). GSI treatment reduced the T cells’ ability to infiltrate the bone
marrow, resulting in few infiltrating T cells (Figure 3.8 A). T cells in the bone marrow
had decreased levels of intracellular Notch1 based on MFI, as shown in Figure 3.8 B.
Circulating levels both of IFN-γ and TNF in mice treated with GSI chow were reduced to
irradiation control levels, as determined by CBA analysis (Figure 3.8 C). In addition to
having an overall decrease in disease severity mice treated with GSI chow were able to
survive significantly longer than mice that did not receive GSI (Figure 3.8 D).Mice
receiving GSI chow had a median survival of 67 days, control chow fed mice had a
median survival of only 21 days. These studies demonstrate that GSI has the ability to be
a potential therapeutic in the treatment of AA, by decreasing the expression of Notch1.
To make our treatment more clinically relevant, we chose to begin GSI treatment
five days after disease induction. To date, the only successful treatment course published
in the literature began one hour post-disease induction (Bloom et al., 2004). Figure 3.9 AD, shows that mice treated with GSI (IP) beginning at day +5 have increased cellularity,
decreased weight loss, and increased circulating red and white blood cells. Treated mice
also had significantly less T cell infiltration into the bone marrow cavity (Figure 3.9 E).
Mice treated with GSI starting at day +5 also had decreased levels of circulating
cytokines IFN-γ and TNF, Figure 3.9 F &G. Currently, additional studies are being
conducted to determine the survival of these treated mice. Taken together, GSI treatment
is effective at decreasing the disease severity of AA- induced mice, even when treatment
is begun at day +5 post disease induction.
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3.2.5 Notch1 and GSI have Slightly Different Targets

There are a multitude of genes that are upregulated in response to Notch1
activation through its binding to CSL and other co-activator molecules. To determine
what targets were affected by inhibition of Notch1, in vitro TH1 polarizations were
utilized to evaluate responses of T cells from N1KO mice compared to GSI-treated wildtype T cells. Experimental conditions and samples used are illustrated in Figure 3.10.
After a period of 72 hours, cells were analyzed for protein expression using flow
cytometry analysis or gene expression by qRT-PCR. Since reports in the literature
indicate several different genes are dysregulated in AA, we wanted to explore genes that
were also Notch1 regulated. Using flow cytometry we first validated that there was in
fact a decrease N1ic in N1KO mice and in wild-type T cells treated with GSI 50μM (3.11
A&B) , both in CD4+ and CD8+ T cell subsets. Flow cytometric analysis based on MFI
showed that T cell subsets were altered in absence of Notch1. Expression of TH1effector
markers T-bet, CD25 and IFN-γ were analyzed in CD4+ T cells. There was a significant
reduction in T-bet expression when Notch1 activity was abrogated either by GSI
treatment or conditional deletion (Figure 3.12 A). We observed a robust reduction of
CD25, but only in GSI-treated samples (Figure 3.12 B). After T cells were restimulated
with anti-CD3, T-bet expression was still decreased in the absence of Notch1 (Figure
3.12 A). However, CD25expression in T cells was refractory to the effects of GSI since
addition of GSI at the time of restimulation had no effect on CD25 expression (Figure
3.12 B). IFN-γ levels were completely abrogated in the T cells polarized in the presence
of GSI, and were reduced in T cells with deletion of Notch1 (3.12 C). Upon examination
of CD8+ T cells we demonstrated there was also decreased expression of T-bet (Figure
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3.13 A), which has been implicated as an important transcription factor in the generation
of short lived effector cells (SLEC). SLECs have been shown to arise in response to IL12, IFN-γ and T-bet. Granzyme B is associated with CTL function and was significantly
reduced in the absence of Notch1 (Figure 3.13B). Similar to what we observed in CD4+ T
cells, there was decreased CD25 expression in the presence of GSI but there were no
differences in the N1KO polarized cells. Treating cells with GSI at restimulation did not
affect CD25 expression (Figure 3.13 C). IFN-γ was abrogated in the presence of GSI and
was reduced in N1KO CD8+ T cells (Figure 3.13 D). When GSI was added at the time of
restimulation, a reduction in IFN-γ was not observed in any of the conditions analyzed in
this set of experiments.
In these studies the percentages of cells expressing TH1-associated proteins were
also evaluated. CD4+ and CD8+ T cells from N1KO and GSI-treated conditions had
decreased Notch1 expression compared to DMSO controls, Figure3.14 A&B. The
percentage of T cells expressing T-bet, or IFN-γ were evaluated in the CD4+ T cells and
showed that their percentages were significantly decreased only in response to GSI
treatment (Figure 3.15 A & B). CD25 percentages were unaffected by abrogation of
Notch1, Figure 3.15 B. Upon the restimulation N1KO CD4+ cells showed significant
decrease in the percent of cells expressing T-bet, Figure 3.15 A. The CD4+ T cells
expressing IFN-γ were reduced in cells only upon GSI treatment, Figure3.15 C. Analysis
of CD8+ T cells showed similar results with decreased percent of cells expressing T-bet,
Granzyme B and IFN-γ (Figure 3.16 A,B &D). There was no difference in the percentage
of cells expressing CD25 in the absence of Notch1, Figure 3.16 C. These findings help to
explain the findings in our model, that mice receiving GSI treatment had better survival
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rates and decreased disease symptoms compared to mice receiving N1KO splenocytes to
induce disease.
To address how Notch1 and GSI affect protein expression we harvested RNA
from our 72 hour time point to look at differences in gene expression of Notch1-regulated
genes. Relative expression of transcripts was determined using the delta, delta CT
method. Samples were normalized to β-actin expression and relative expression was
based on CT values of naive CD4+ and CD8+ T cells. The genes examined were chosen
based on previously reported genes that are dysregulated in AA and genes that are
believed to be Notch1 regulated. In Figure 3.17 we evaluated notch1 (A), notch2 (B),
tbox-21(C), and hes1 (D), gzmb (E), ifng (F) and pf4 (G). Surprisingly we saw no
differences in any of the genes analyzed, with the exception of Notch1 in N1KO cells
(Figure 3.17 A). These data suggest that there is some other way in which the loss of
Notch1 affects expression of these target proteins.

3.2.6 Long-Term Treatment with GSI Does Not Affect Hematopoiesis

Notch proteins have been shown to be important in many cell fate decisions
during hematopoiesis (Duncan et al., 2005). Although these studies suggest a more
important role for Notch2, rather Notch1, GSI inhibits activation of all members of the
Notch family. To ensure that long-term GSI treatment would not affect normal
hematopoiesis, long-term GSI treatment studies were done. These experiments are
outlined in Figure 3.18. After six months on control or GSI chow (5mg/kg), bone marrow
cells were isolated and used to reconstitute lethally-irradiated recipients, of these mice
some were continued on chow during the period of engraftment. Mice were reconstituted
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for a period of four months. After four months all mice were sacrificed for analysis of
engraftment and stem cell repopulating capabilities. Bone marrow cells were harvested
and again used to reconstitute another group of lethally-irradiated mice. These mice were
allowed to reconstitute for 2 months. During both the first and second reconstitution,
mice that received BM either from control chow or GSI chow-fed animals had no
differences in their survival rates. At the time of harvest, mice fed GSI had similar BM
cellularities after 6 months (Figure 3.19 A). Mice that were serially transplanted (4 and 2
months) also had similar cellularities regardless of which type of chow they received
(Figure 3.19 B-C). BM cells from both control and GSI chow treated groups showed
similar capacity to differentiate along all lineages in clongenic assays performed after 6
months on GSI chow, or after serial transplantations (4 and 2 months). Colonies were
quantified, shown in Figure 3.20 A-C. All GSI recipient mice had similar percentages of
lineage positive cells in the bone marrow compared to their control fed counter parts, at
all-time points (Figure 3.21 A-C). Hematopoietic stem cell values were also equivalent
between GSI and control fed mice (3.22 A-E). HSC percentages were determined by
gating on lineage negative CD34-/LO cells. Percentages of cells positive for the markers
Sca-1, c-kit and HSCs (double positive cells for Sca-1 and c-kit) were then analyzed.
These studies conclude that long term treatment with GSI does not impact normal adult
hematopoiesis after six months of treatment. Moreover, administering GSI to mice during
the reconstitution period appeared to have no effect on the stem cells’ ability to engraft
the lethally-irradiated hosts.
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3.3 Discussion

Unlike many other published reports these data, for the first time, identify targets
of Notch1 through its genetic deletion. Much of the published data in the field have used
several ways of abrogating Notch including GSI treatment and dominant negative forms
of master mind. These data suggest that although GSI inhibits Notch1 expression there
appear to be additional targets that are not mediated by Notch1. Differences in the effects
of GSI and genetic deletion of Notch1on downstream targets may result from how
Notch1is inhibited. GSI inhibits Notch1 at the level of the protein activation, while
conditionally deleting Notch1 prevents its production at the transcription level.
Regardless of the exact mechanism of how Notch1 inhibition affects the proteins
examined here, it is clear that Notch1 plays a role in the disease progression of our
murine model of AA.
Mice that received N1KO splenocytes had delayed disease onset and decreased
disease severity compared to controls. Similarly, we were able to recapitulate this disease
rescue when treating AA mice with GSI by two routes of administration, even when
treatment was started five days post disease induction. Treatment with GSI resulted in a
consistently more robust rescue than that of the Notch1 conditional knock-outs. After our
in vitro analysis we believe this could be explained by several observations. First is
through the decrease in CD25+ and IFN-γ expression that was observed in GSI-treated
cells as opposed to Notch1 deficient cells. Additionally cells treated with GSI showed not
only decreases in protein expression per cell as determined by MFI, there was also a
significant decreases the percent of cells expressing each protein with GSI treatment but
not when N1KO T cells. This observation suggests that another target of GSI is being
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affected or perhaps another Notch (2-3) is compensating in the loss of Notch1 although
this unlikely since we did not observe robust changes in Notch2 or 3.
To ask the question of how Notch1 is effecting disease progression we performed
in vitro polarization assays which determined that inhibition of Notch1 led to a decrease
in the protein expression of T-bet, Granzyme B and IFN-γ. Inhibition of Notch1 through
genetic means or with the treatment of GSI leads to slightly different patterns of protein
expression. Although there are dramatic differences in protein expression, qRT-PCR
revealed that there were no significant alteration in the gene expression when Notch1 was
conditionally deleted or inhibited with GSI. The mechanism which leads to decreased
protein expression remains unclear although we speculate it could be through the
regulation of microRNAs
The delayed disease onset in mice in which Notch1 is inhibited is consistent with
an observation made by Anushka Dongre (unpublished) that, at 24 hours, there are
apparent defects in IL-2 production, IL-2 receptor expression (CD25) and expression of
CD69 (very early antigen). However after 72 hours this defect is no longer observed,
suggesting that there is an initial delay in T cell activation, but it is able to recover after
extended stimulation. This delay in T cell activation may be a result of defective NF-κB
signaling in the absence of Notch1. This defect may be due to decreased nuclear retention
of NF-κB by Notch, or insufficient formation of the CBM complex when Notch acts as a
scaffolding protein. These possibilities correspond with another observation made in our
lab (Christina Arieta and Gaberila Gonzalez-Perez) that inhibition of NF-κB through
genetic and biochemical approaches also lead to delayed disease onset in AA mice.
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A recent publication implicated Notch as an essential regulator in another GVHD
model (Zhang et al., 2010). In this publication Notch was abrogated using a dominantnegative mastermind mouse. This study showed that dominant negative mastermind
donor cells became less activated (by CD25 expression) and had decreased expression of
IFN-γ, granzyme B, perforin and IL-2, by qRT-PCR. These results vary from what we
saw in our studies looking at the gene transcription regulated by Notch1. These
discrepancies can be attributed to different methods of inhibiting Notch. It is important to
note that a decrease in Notch activation was not validated in these studies. This report
also demonstrated that there was no reduction in T-bet levels, in donor dominant negative
mastermind T cells. This observation is consistent with our results showing there is no
difference in T-bet expression by gene transcription when Notch1 is inhibited. Our data
clearly demonstrates that in the absence of Notch1 we dramatically decrease the protein
expression of the master TH1 regulator, T-bet.
Our studies concluded that long-term treatment with GSI had no detrimental
effects on hematopoiesis. Hematopoiesis was determined not to be affected based on the
stem cells ability to engraft lethallyiirradiated mice, clongenic assays and flow cytometry
analyses of lineage differentiation and HSC population. Each of these tests showed no
significant difference in the repopulation capacity of BM cells from mice that received
control or GSI chow. This suggests that GSI could be used as an immunosuppressive to
treat of AA with no detrimental effects on hematopoiesis or engraftment if patients were
then eligible to receive a BM transplant. Additionally, inhibition of Notch1 in a BMT
model was shown to decrease GVH response. This observation suggests that continued
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GSI treatment after a BMT would decrease the likely hood of GVH response (Zhang et
al., 2010), but still allow for complete engraftment of stem cells.
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Figure 3.1. Notch1 Activation is Increased in T Cells in AA Induced Mice
Bone marrow cells and splenocytes were isolated and stained with antibodies specific for
CD4, CD8 and intracellular Notch1. Increased N1ic expression can be observed by the
shift in MFI represented in the histogram overlay (A). Quantification of N1ic by MFI
expression in each T cell subset is collated in the graph (B).
**P<0.01
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Figure 3.2. Upregulation of Notch in AA Mice, Specifically Notch1
Isolated CD4 and CD8 T cells from the spleen and bone marrow of diseased mice
showed significant increase in the expression of notch1 (A), but not notch 2 (B) or notch3
(C). Additionally, the transcriptional activator of Notch1-regulated genes, rbpj, was
increased in splenic T cells compared to control T cells (D). All genes were normalized to
β-actin and their relative expression was based on CD4 and CD8 T cells isolated from the
spleens of irradiation-control mice. Values were determined using the delta, delta CT
method.
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Figure 3.3. Validation of Notch1 Conditional Knock-out Mice
A schematic demonstrating our floxing protocol and experimental methodology used to
validate Notch1 deletion (A). qRT-PCR demonstrated that Notch1 gene expression was
significantly decreased following our floxing protocol in splenic T cells isolated from
N1KO mice compared to Cre and Poly IC controls (B). Decreased protein expression of
N1ic was also observed using flow cytometry (C). CD4 and CD8 percentages in N1KO
mice and controls showed no significant differences by flow cytometry analysis (D).
*P<0.05, **P<0.01, ***P<0.001
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Figure 3.4. Mice that Receive Notch1 Deficient Splenocytes have Intermediate
Disease Phenotype
Mice that received N1KO splenocytes had significantly higher BM cellularities at the
time of harvest on day 17 (A). These mice also presented with less weight loss and
increased white and red blood cells compared to control induced mice (B-D). CBA
analysis revealed that Notch1 presence or absence in bulk splenocytes had no affect on
the amount of circulating IFN-γ and TNF (E&F).
*P<0.05, **P<0.01
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Figure 3.5. Notch1 Deficient T cells Fail to Infiltrate the Bone Marrow which Leads
to Increased Survival
Donor-derived T cells from N1KO mice were significantly reduced in the BM by FACS
analysis, compared to control induced animals (A). The T cells that did infiltrate the bone
marrow in N1KO recipient F1 mice had decreased intracellular Notch1 levels based on
MFI expression (B). N1KO recipient mice succumbed to disease later than control
induced animals. (C) Median survival times for recipients were 19 days for Cre controls,
21 days for PolyIC controls and 25 days for N1KO induced mice.
*P<0.05, **P<0.01
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Figure 3.6. Notch1 is Decreased in vivo after Treatment with GSI chow
Mice were fed GSI chow (5mg/kg) for two weeks after which time splenocytes were
harvested. Splenocytes were stimulated with plate bound anti-CD3 and anti-CD28 for 24
hours. Splenocytes were then stained for CD4, CD8 and N1ic and analyzed by flow
cytometry. MFIs are represented by a histogram looking at intracellular Notch1 in CD4
(upper) and CD8 cells (lower panels). CD4 cells had 24.8% less N1ic expression
compared to control fed mice and CD8 cells had 26.3% less N1ic expression. Data are
representative of one experiment.
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Figure 3.7. GSI Treatment Ameliorates Bone Marrow Failure
Mice were treated with GSI (LY575411) by two routes, orally (in rodent chow) or by
intraperitoneal injection. Treated mice had increased bone marrow cellularities and
increased circulating levels of white and red blood cells (A-C). Mice treated with GSI
also had decreased amounts of weight loss (D). Values for all controls and AA-induced
mice are shown in the graphs on the left and values for AA-induced treated or untreated
mice are shown in the graphs on the right.
*P<0.05, **P<0.01, ***P<0.001
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Figure 3.8. GSI Treatment Decreases T cell Infiltration and Increases Survival Time
GSI treatment by either route of administration resulted in significant reduction of
infiltrating T cells into the BM (A). GSI chow-treated mice had decreased intracellular
Notch1 levels compared to control fed mice (B). CBA analysis of INF-γ and TNF
showed significant reduction in the level of these circulating cytokines when treated with
GSI chow (C&D). Decreased disease severity led to increased survival time of mice
treated with GSI chow, compared to mice fed control chow (E).
*P<0.05, **P<0.01, ***P<0.001
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Figure 3.9. Therapeutic Administration of GSI Attenuates Disease
Mice treated with GSI, starting at day 5 post disease-induction show rescue of BM
cellularity, weight loss and peripheral pancytopenia (A-D), and reduced T cell infiltration
into the bone marrow (E). Mice treated beginning at day 5 also had slightly decreased
levels of inflammatory cytokines (F&G)
**P<0.01, ***P<0.001
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Figure 3.10. Experimental Outline of in vitro Studies
Bulk splenocytes were isolated and CD4+ and CD8+ T cells were separated using the
IMAG system. Co-cultured CD4 and CD8 T cells were stimulated under TH1 polarizing
conditions for 72 hours. At that time some cells were re-plated and stimulated with antiCD3 for an additional 5 hours, in the presence or absence of GSI. All samples were then
stained and analyzed by flow cytometry.
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Figure 3.11. Successful Reduction of Notch1 Protein Expression
Levels of N1ic were significantly reduced in CD4 and CD8 T cells that were treated with
GSI or isolated from N1KO mice (A&B).
**P<0.01, ***P<0.001
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Figure 3.12. Decreased TH1-Associated Proteins in CD4+ T cells
CD4+ T cell were gated on and the MFI levels of T-bet (A) CD25 (B) and IFN-γ (C) were
determined. GSI-treated and N1KO T cells showed significant reduction of T-bet levels.
CD25 expression was decreased when GSI was added at time 0, but not prior to the
restimulation. IFN-γ was reduced in the absence of Notch1 both in GSI-treated and in
N1KO cells (C).
*P<0.05, **P<0.01, ***P<0.001
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Figure 3.13. Decreased CTL Associated Proteins in CD8+ T Cells
CD8+ T cell were gated on and the levels of T-bet (A), Granzyme B (B), CD25 (C) and
IFN-γ (D) were analyzed by MFI. GSI and N1KO T cells showed significantly reduced
levels of T-bet and Granzyme B. CD25 expression was altered in the presence of GSI at
time 0, but not prior to the restimulation. IFN-γ was reduced in the absence of Notch1
both in GSI-treated and N1KO T cells.
*P<0.05, **P<0.01, ***P<0.001
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Figure 3.14. Decreased Percentages of T cells Expressing Notch1 After its
Abrogation
Flow cytometric analysis of CD4 (A) and CD8 (B) T cells showed a reduction in the
percent of T cells that were expressing intracellular Notch1 after 72hrs stimulation and a
5hr restimulation. Adding GSI at the time of the restimulation had no effect on
Notch1expression.
*P<0.05, **P<0.01, ***P<0.001
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Figure 3.15. Reduced Percentages of CD4+ T Cells Expressing TH1 Associated
Proteins
CD4+ T cell were gated on and the percentages of cell expressing T-bet (A), CD25 (B),
and IFN-γ (C) were analyzed by flow cytometry. GSI treatment decreased percentages of
cell expressing T-bet and IFN-γ; however, N1KO T cells did not show robust differences
in the percentage of cells expressing T-bet or IFN-γ. Percentages of cells expressing
CD25 were not altered under any conditions.
*P<0.05, ***P<0.001
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Figure 3.16. Reduced Percentages of CD8+ T cells Expressing CTL Associated
Proteins
CD8+ T cells were gated on and the percentages of T-bet (A), Granzyme B (B) CD25 (C),
and IFN-γ (D) were analyzed by flow cytometry. GSI treatment resulted in decreased
percentages of cells expressing T-bet, Granzyme B and IFN-γ; however, N1KO T cells
did not show robust differences. Percent of cells expressing CD25 were not altered under
any conditions.
*P<0.05, **P<0.01, ***P<0.001
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Figure 3.17. Regulation of TH1-Associated Proteins by Notch1 is not Transcriptional
After 72 hours, RNA was isolated from CD4+ and CD8+ TH1 polarized cells. The
following genes were then analyzed in triplicate: Notch1 (A), Notch2 (B), T-bet(C), Hes1
(D), Granzyme B (E), IFN-γ (F) and platelet factor four (G). These genes were chosen
based on previous analyses of dysregulated genes in AA mice.
**P<0.01
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Figure 3.18. Experimental Outline of Long-Term GSI Treatment Studies
Mice were fed GSI or control chow for 6 months beginning at 6 weeks of age. Mice were
sacrificed and BM cells were isolated. Total BM cells were used to reconstitute a group
of lethally-irradiated animals. Of this group, some mice were maintained on GSI chow
during the reconstitution period of 4 months. After 4 months mice were sacrificed and
total BM cells were isolated and used to reconstitute a second group of lethally irradiated
mice. The second group of animals was allowed to reconstitute for 2 months. Of this
group, some mice were maintained on GSI chow during the reconstitution period of 2
months.
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Figure 3.19. Long-Term Exposure to GSI does not Affect BM Cellularity
After 6 months on control or GSI show mice showed no difference in the number of
nucleated cells in the bone marrow (A). Mice that were reconstituted from the 6 month
group also showed no differences in cellularities between control and GSI recipients.
Additionally mice maintained on GSI during the reconstitution period did not have
altered cellularities (B). The second group of recipient mice was reconstituted for 2
months, at which time there was no difference in mean cellularities between groups.
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Figure 3.20. HSC from GSI-Treated mice can Repopulate Clongenic Assays
Clongenic assays were performed according to the manufacturer’s protocol and were
plated in duplicate. Colonies were counted after 12-14 days of culture. HSCs from both
control- and GSI-fed mice were able to produce equal colony numbers (A). The first
groups of reconstituted mice were also able to repopulate clongenic assays, even when
maintained on GSI chow during engraftment (B). The second transplanted group showed
similar capabilities to repopulate clonogenic assays and had equal number of colonies.
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Figure 3.21. Long Term GSI Treatment does not Affect Development of any BMderived lineages
Bone marrow cells from each group and condition were isolated and stained for flow
cytometric analysis using a lineage kit (BD). There were no differences in the
percentages of each lineage analyzed including B220, CD3, CD 11B, Ly-6G, Ter119 or
total amount of lineage positive cells between control- or GSI chow-fed mice. Samples
analyzed were from mice fed either control or GSI chow (A), four month reconstituted
mice from donors that received control or GSI chow (B), or mice that received bone
marrow from the “First Reconstitution” group (C).
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Figure 3.22. GSI does not Perturbed Stems Cell Percentages
BM cells were isolated and stem cells were quantified using flow cytometric analysis.
Bone marrow cells were stained for the lineage markers, CD34, c-kit and Sca-1. Stem
cells (HSC) were determined to be lineage-, CD34-/lo, c-kit+ and Sca-1+. These cells were
then quantified for each group including 6 month treated (A), 4 month reconstituted
(“First Reconstitution”) (B) and 2 month reconstituted animals, (“Second Reconstitution)
(C). There were no deficiencies or differences in stem cell percentages under any of the
GSI-treated conditions.
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CHAPTER 4
PKC-Θ IN A MURINE MODEL OF APLASTIC ANEMIA

4.1 Introduction

Therapies targeted towards the prevention of T cell activation, such as
cyclosporine A, when used in combination with ATG, have proved to be effective in
decreasing disease severity of AA. Therefore, we wanted to determine if PKC-ζ, a key
player in T cell activation, was involved in the disease progression in our model of AA.
PKC-ζ was first implicated in AA when one study discovered that treating CD4+ T cells
from AA patients with rottlerin (a PKC-ζ inhibitor) resulted in down regulation of T-bet
(Solomou et al., 2006). Rottlerin was also shown to dramatically decrease human CD4+
and CD8+ T cells’ ability to become activated using an in vitro system (Springae et al.,
2007). Rottlerin is believed to inhibit PKC-ζ by competing with ATP binding.
Subsequently, this leads to inhibition of PKC-ζ phosphorylation and reduces its activity
on its substrates. Based on PKC-ζ’s essential role in T cell activation it is likely to play
an important role in mediating T cell activation, proliferation and tissue destruction in our
model of AA.
The availability of PKC-ζ null mice on a C57BL/6 background allowed us to first
validate PKC-ζ through genetic means, by using them as bulk splenocyte donors, which
are then infused into our F1 hybrids. PKC-ζ knockout mice were generated by Dan
Littman’s group in 2000 (Sun et al., 2000). These mice lead to the discovery that loss of
PKC-ζ results in deficiencies in TCR-induced activation in mature, but not immature T
cells. PKC-ζ knock-out mice have been well-documented to have normal TH1 responses
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to viral infection, but in the following studies we observed defective T cell responses to
the MHC mismatch GVHD used in this model.
In addition to determining if PKC-ζ had an important role in mediating disease we
also wanted to determine in which cellular subset PKC-ζ was necessary to mediate
disease and bone marrow destruction. To complete these studies we used add back
experiments in which we combined CD4+, CD8+ and APCs in different combinations
from wild-type and PKC-ζ-/- mice. These combinations of wild-type and PKC-ζ-/- cells
were then added back to recipient mice as outlined in Figure 4.4; disease was then
evaluated at day 17.
PKC-ζ has been shown to be important in the production of T regulatory cells,
which are necessary to maintain immune homeostasis. Because PKC-ζ-/- mice showed
decreased number of Tregs in the peripheral pool (Jeremy Samon, unpublished
observation) we asked whether loss of PKC-ζ in the recipient mice influenced disease
severity in PKC-ζ deficient F1 hybrids. Deficiency in the Treg pool has also been
observed in patients with AA. This mechanism is driven by the loss of NFAT1
expression in patients with AA that subsequently leads to decreased FOXP3 expression,
the master transcriptional regulator of Treg differentiation (Solomou et al. 2007).
Similar to our experiments exploring the role of Notch1 in AA and GSI as a
therapeutic, we examined whether rottlerin held potential to be a viable therapeutic
option. Therefore, AA mice were treated with rottlerin and disease symptoms were
analyzed. We performed therapeutic studies in which we began treatment either 1 hr after
disease induction or +10 days after disease induction. Since PKC-ζ is vital in T cell
activation it has been implicated in disease progression of many T cell mediated
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autoimmune diseases and is an excellent therapeutic target due to it specific expression in
T cells (Baier and Wagner, 2009).

4.2 Results

4.2.1 Mice that receive PKC-θ-/- Splenocytes Fail to Develop Disease Symptoms
To determine if PKC-ζ plays a role in our murine model of AA we first used a
genetic approach. To address this in our model we used PKC-ζ-/- mice as bulk splenocyte
donors and compared disease to F1 recipients that received bulk splenocytes from wildtype donor. Mice that received PKC-ζ-/- splenocytes failed to develop any disease
symptoms; they exhibited normal BM cellularity, no observed weight loss or decreased
peripheral blood counts, unlike their wild-type-induced litter mates (Figure 4.1 A-D).
Additionally these mice were able to survive long past wild-type controls to day 31 at
which point they were humanly euthanized. At day 31 there were no signs of disease as
determined by cellularity, weight loss and peripheral blood values (Figure 4.1 A-D).
Additionally there was no T cell infiltration into the bone marrow of mice induced with
PKC-ζ-/- splenocytes either at day 17 or day 31 post-disease induction (Figure 4.2 A).
Finally, there was no increase in the amount of IFN-γ or TNF in the circulation of mice
induced with PKC-ζ-/- splenocytes compared to WT induced controls Figure 4.2 B.
Using GFP+ PKC-ζ-/- mice or GFP+ wild-type allowed us to locate the donor
splenocytes, to address the question of whether PKC-ζ-/-splenocytes did not survive in
recipients or whether they failed to infiltrate the bone marrow. At day 17, there was very
little GFP expression in any of the secondary lymphoid organs or circulating in the blood
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whereas WT controls had massive infiltration of donor-derived cells in all tissues
examined (Figure 4.3 A&B). This finding was suggestive that the cells deficient in PKCζ do not survive in the circulation as inactivated T cells, and most likely undergo
apoptosis, as had been shown in the literature. To determine the expansion of donor T
cells over the disease time course the mice were induced with AA and harvested at the
following time points post-induction: days 3,6,9,12,13,15 and ending with day 17. We
discovered that, unlike wild-type T cells, PKC-ζ-/- T cells failed to expand above 5% at
any time point in any of the organs analyzed, with the percent GFP-positive expression
peaking around day 12 and decreasing until day 17 (Figure 4.3 B). The control-induced
mice had massive expansion of GFP+ donor cells in the circulation and in the lymphatic
system beginning at day 13 (Figure 4.2 A). Using flow cytometry, T cell expansion was
measured by GFP expression present in the spleen, peripheral blood and BM as well as in
the cervical, axillary, mesenteric and inguinal lymph nodes.

4.2.2 PKC-θ Drives Disease in the CD8+ Compartment of T cells
Our original hypothesis was that PKC-ζ was essential to initiate disease
specifically in the CD4+ T cell compartment. This hypothesis was based on observations
in the literature that CD4+ TH1cells are believed to be the initiating cell type in
autoimmune disorders such as AA. In order to define which T cell compartment (CD4 or
CD8) was essential for mediating disease, we performed a series of add-back experiments
consisting of wild-type and PKC-ζ-/- T cells in different combination. To distinguish
between WT and PKC-ζ-/- T cells, we used GFP+ PKC-ζ-/- and WT GFP-. Add-back
experiments were performed using the combination of T cell subsets and genotypes

78

shown in the schematic in Figure 4.4. Interestingly, we found that loss of PKC-ζ in CD4+
T cells was not sufficient to prevent disease whereas loss in CD8+ T cells was unable to
initiate disease. We evaluated disease by BM cellularity weight loss and peripheral
pancytopenia. We observed that mice receiving PKC-ζ-/- CD4+, WT APCs and WT CD8+
induced mice developed severe hypocellular BM equivalent to control WT-induced mice
(Figure 4.5 A). Using this combination of T cells with PKC-ζ-/- APCs resulted in similar
levels of hypocellularity (Figure 4.5 A). Mice that were induced with WT CD4+ with
PKC-ζ-/- CD8+, and either PKC-ζ-/- or WT APCs, had normal cellularities (Figure 4.5 A)
When we isolated both T cell subsets from WT mice and added them to PKC-ζ-/- APCs
we observed levels of hypocellular BM similar to WT-induced controls (Figure 4.5 A)
Mice that received PKC-ζ-/- T cells and WT APCs exhibited normal BM cellularities
(Figure 4.5A). We observed similar trends in weight loss for each condition as we with
the BM cellularities (Figure 4.5B). When observing peripheral values we saw marked
decreases in the circulating white blood cells in the following three conditions, WT
induced, PKC-ζ-/- CD4+, WT APCs and WT CD8+ and WT CD4+, WT CD8+, PKC-ζ-/APC (Figure 4.6 A). Similar to what we observed in circulating levels of white blood
cells, the same three induction conditions resulted in decreased levels of circulating red
blood cells (4.6 B).
Infiltration of cells to the BM in add-back experiments demonstrated a very
interesting pattern. Mice that received CD4+ WT cells and CD8+ KO cells (with either
source of APCs) failed to develop infiltration into the bone marrow cavity of either CD4
or CD8 T cell subset, similar to that seen with of PKC-ζ-/- induced mice (Figure 4.7
A&B). However WT CD8+ T cells were capable of initiating infiltration of both WT
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CD8+ cells and PKC-ζ-/- CD4+ T cells, but only in the presence of WT APCs (Figure 4.7
A&B). Using the combination of PKC-ζ-/- CD4+, WT CD8+ and WT APCs also led to
increased CD8+ T cell infiltration. This finding is suggestive that PKC-ζ-/- may also play a
role in the T cell depleted population. Mice that received T cells of both subtypes, either
WT CD4+, CD8+ plus PKC-ζ-/- APCs or PKC-ζ-/- CD4+, CD8+ and WT APCS, mimicked
T cell infiltration in WT-induced or PKC-ζ-/- -induced animals, respectively. This
observation demonstrated that intact PKC-ζ in the CD4 and CD8 T cells takes precedent
over PKC-ζ expression in the APC subset (Figure 4.7 A&B).

4.2.3 PKC-θ-/- Signaling is only Essential in the Donor T cell Compartment

To determine if decreased Treg pools in recipient mice influence disease severity
we created F1 hybrids that were PKC-ζ-/-. These mice were generated as outlined in the
Materials and Methods. Mice were determined to be PKC-ζ-/-as evaluated by genotyping
and western blot. Lysates prepared from total splenocytes demonstrated that there was no
protein product detected in PKC-ζ-/- F1 hybrids, whereas intact PKC-ζ was detected in
F1xF1 hybrid controls, Figure 4.8. PKC-ζ-/- F1 hybrids or F1 controls were induced and
monitored for signs of disease until day 17. At that time BM cellularity, weight loss,
peripheral pancytopenia, and T cell infiltration was analyzed. Increased disease severity
in the PKC-ζ deficient recipients was not observed, compared to control recipients,
Figure 4.9 A-D. Additionally there were no differences in the levels of circulating
cytokines of IFN-γ or TNF between wild type and PKC-ζ-/- F1s. Since we observed no
clear differences in the two groups additional experiments were not pursued.
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4.2.4 Rottlerin is an Inhibitor of PKC-θ
Rottlerin was first described as an inhibitor of PKC-δ (Gschwendt et al., 1994).
Later studies revealed this was not the case and identified it as a PKC-ζ inhibitor (Soltoff,
2007). Rottlerin has been shown to prevent phosphorylation and subsequent kinase
activity of PKC-ζ (Springael et al., 2007). To demonstrate rottlerin as an in vivo inhibitor
of PKC-ζ, we treated mice for 5 days with IP injections of rottlerin at a dose of 10mg/kg.
CD4+ T cells were isolated by positive selection and stimulated with plate-bound antiCD3 and anti-CD28 for 48 hours. Cell lysates were prepared and analyzed by western
blot. To ensure that rottlerin was preventing phosphorylation of PKC-ζ we probed blots
for total PKC-ζ and phospo-PKC-ζ (Figure 4.10 A). A clear decrease in the
phosphorylation of PKC-ζ was observed in mice that were treated with rottlerin,
documenting its effectiveness in vivo.

4.2.5 Rottlerin Treatment Results in Complete Disease Abrogation
Once we validated rottlerin as an inhibitor of PKC-ζ we began toxicity studies to
ensure there were no adverse side effects. After a 17 day treatment with rottlerin there
was no apparent defect in total T cell percentages in either T cell compartment, data not
shown. We then began treating AA-induced mice daily, beginning one hour after disease
induction. Mice that received rottlerin treatment had increased BM cellularity and no
weight loss, peripheral pancytopenia or T cell infiltration, Figure 4.11 A-E. Using GFP+
mice as donors, we determined there was no expansion of donor-derived T cells in the
host, as quantified by flow cytometry (Figure 4.12 A). Also there was no increase in the
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levels of IFN-γ or TNF, Figure 4.11 F-G. Treatment with rottlerin resulted in complete
disease abrogation, but had no ill effects on non-activated host T cells (Figure 4.12 B).
Mice treated with rottlerin exhibited no signs of disease when treatment was
begun 1hr post disease induction. With such robust rescue, we decided to begin rottlerin
treatment starting at day 10. This time point was chosen because T cells in the spleen
don’t begin expanding until day 9 (Figure 4.3 A). Preliminary studies dosing at 10mg/kg
daily did not result in disease rescue, therefore in subsequent studies we administered a
dose of 20mg/kg a day of rottlerin. Mice that received rottlerin treatment had increased
BM cellularity, decreased weight loss and increased numbers of circulating white and red
blood cells (4.13 A-D). Rottlerin-treated mice also had decreased infiltration into the
bone marrow cavity (4.13 E), and decreased levels of the inflammatory cytokines, IFN-γ
and TNF (4.13 F&G). These experiments outline the excellent reduction in T cellmediated destruction resulting from using rottlerin administered in a clinically-relevant
time frame.

4.3 Discussion
Using our mouse model of AA we have established that PKC-ζ is essential for the
initiation of disease. T cells deficient in PKC-ζ fail to expand and proliferate in response
to the MHC (H2b into H2d) mismatch, as has been documented previously (Lei et al.,
2009). These studies demonstrate that PKC-ζ deficient cells undergo apoptosis in our
murine model in response to the MHC mismatch, since the percent of T cells in the
circulation decreases over the disease course from day 3 to day 17. There are several
studies in the literature that have shown that in the absence of PKC-ζ stimulation of T
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cells results in accelerated apoptosis. PKC-ζ is needed during T cell stimulation to
counteract the actions of the pro-apoptotic molecule BAD. It is also required for the
upregulation of Bcl-xL and Bcl-2, which is anti-apoptotic molecules (Bertolotto et al.,
2000; Villalba et al., 2001; Hindley et al., 2001; Manicassamy et al., 2006). We believe
that these mechanisms are also playing a role in inducing apoptosis of PKC-ζ deficient
cells in out AA model.
Another mechanism that could be responsible for the decreased survival of
PKC-ζ-/- T cells is defective IL-2 production. Mature T cells from PKC-ζ knockout mice
have defects in NF-κB-mediated production both of IL-2 and its receptor CD25 (Sun et
al., 2000). Additionally, findings that abrogation of NF-κB activity, through genetic or
biochemical approaches also resulted in decreased disease severity in our model of AA
(Christina Arieta and Gabriela Gonzalez-Perez, unpublished data).
Using add-back studies, CD8+ T cells were found to be the T cell compartment
necessary for the development of disease in AA mice. Other GVHD models have
established that in acute models, such as the model of AA we created, GVHD is mediated
by CD8+ T cells, while models of chronic GVHD are mediated by CD4+ T cells (Yu et
al., 2006). In our model of AA we did not observe any signs of chronic GVHD in mice
induced with wild-type CD4+ cells. These results could be attributed to several different
factors. One possibility is that mice receiving CD4+ wild-type cells were not allowed
enough time to develop chronic GVHD and were sacrificed at day 17 before onset of any
symptoms. Another possibility is that the number of cells which we use to induce disease
is not sufficient to induce a chronic response.
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CD8+ T cells have been found to be more efficient in mediating acute GVHD due
to their ability to recognize MHC mismatch on both donor and host APCs. On the
contrary, CD4+ T cells are only capable of recognizing responses to donor APCs (Yu et
al., 2006). The most valuable and interesting finding of our add-back experiments is that
the process of T cell activation and expansion in the WT CD8+ T cells allowed for the
expansion and infiltration of the CD4+ PKC-ζ-/- This observation suggests that the
secretion of cytokines such as IL-2 may supply this necessary growth factor to allow the
expansion of CD4+ PKC-ζ -/- T cells. However these studies also demonstrated that WT
CD8+ T cells needed WT APCs (donor derived) to be present to allow for this expansion
and infiltration of PKC-ζ-/- CD4+. Although the combination of WT CD8+, PKC-ζ-/-CD4+
and WT APCs lead to disease symptoms, the combination of WT CD4+ and CD8+ T cells
with PKC-ζ-/- APCs had the most robust disease induction compared to WT induced
mice. This suggests that although we may have found a role for PKC-ζ in the T celldepleted population, when PKC-ζ is present in both T cell subsets PKC-ζ-/- APCs are
sufficient to induce disease. In conclusion, these studies demonstrated that PKC-ζ
expression in CD8+ cells is necessary for the development of disease in our model of AA.
However, these studies do not rule out that CD4+ WT cells are not sufficient to induce
disease. CD4+-mediated responses may take a longer period to develop than the 17 day
time course used here. Additionally, we may have discovered a novel role for PKC-ζ in
donor APCs.
Although mice deficient in PKC-ζ have been shown to have decreased numbers
of Tregs in their peripheral pool (Jeremy Samon, unpublished observation), we observed
no signs of accelerated disease when F1 PKC-ζ-/- mice were induced. Compared to F1xF1
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hybrid controls, induced PKC-ζ-/- mice had decreased BM cellularity, increased weight
loss, peripheral pancytopenia, robust T cell infiltration into the bone marrow and
increased levels both of IFN-γ and TNF (Figure 4.9 A-G). These results demonstrate that
the presence or absence of PKC-ζ in recipient mice does not accelerate or inhibit disease
progression in our model of AA. This finding suggests that our model may not be a good
resource for studying whether T regulatory cells play protective role patients with AA.
Currently PKC-ζ inhibitors have been used clinically for the treatment of different
cancers (http://clinicaltrials.gov/, 2011). In the literature there have been very few studies
looking at the therapeutic benefits of rottlerin in other models of autoimmune disorders.
This finding is very interesting considering how many autoimmune models have
implicated PKC-ζ as playing a role in disease progression (Salek-Ardakani et al., 2005;
Tan et al., 2006; Salek-Ardakani et al., 2004; Nagahama et al., 2008; Healy et al., 2006).
In this AA model rottlerin was a very effective inhibitor of T cell activation that resulted
in complete disease abrogation when delivered 1hr post disease induction and provided
substantial rescue even when treatment was begun +10 days after disease induction.
Treatment with rottlerin showed no toxicity towards host T cells that were not activated;
only T cells that were activated were affected by rottlerin treatment (Figure 4.12 A&B).
These experiments showed for the first time showed the essential role of PKC-ζ in
the development of BMF in our AA model. These findings also show that the robust
expansion which is seen in induced animals can be completely eliminated with treatment
of rottlerin. Additional studies with other PKC-ζ inhibitors that have been used clinically
would further support the use of PKC-ζ inhibitor in the treatment of AA patients.
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Figure 4.1. Mice that Receive PKC-θ-/- Splenocytes do not Develop Disease
Mice induced with PKC-ζ-/- splenocytes have increased survival; some mice were
harvested on day 31. Mice do not exhibit hypocellular bone marrow (A), weight loss (B)
or peripheral pancytopenia (C&D)
*P<0.05, ***P<0.001
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Figure 4.2. PKC-θ -/- Fail to Infiltrate the Bone Marrow or Induce Cytokines
Bone marrow cells were stained with antibodies specific for CD4 and CD8 analyzed by
flow cytometry to determine the percent of CD4+ and CD8+ infiltrating T cells. Mice that
received PKC-ζ-/- cells had no infiltration at either of the time points analyzed (A). CBA
analysis of the plasma isolated from these mice showed no differences in the levels of
circulating cytokines, IFN-γ and TNF, compared to irradiation controls (B).
*P<0.05, ***P<0.001.
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Figure 4.3. PKC-θ Deficient T cells Fail to Expand in F1 Recipients
A time course was performed to look at the expansion of donor WT versus PKC-ζ-/- T
cells. Mice were induced either with WT or PKC-ζ-/- splenocytes, and then sacrificed at
days 3, 6, 9, 12, 13, 15 ending with day 17. To track donor T cells GFP+ WT or PKC-ζ-/mice were used as donors. At each time point T cell expansion was analyzed in the
following organs; spleen, lymph nodes (cervical, axillary, mesenteric, inguinal),
peripheral blood and bone marrow. GFP expression was quantified by flow cytometric
analysis for WT (A) or PKC-ζ-/- T cells (B). There was no increase in GFP-expressing
PKC-ζ-/- T cells (B) at any of the time points or tissues analyzed, compared to the rapid
expansion of WT donor T cells (A).
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Figure 4.4 Schematic for Add Back Experiments using PKC-θ-/- Subsets
The combination of cell types shown will be used to induce F1 recipients. Disease
severity will be evaluated on day 17.
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Figure 4.5. Disease Develops only in the Presence of Wild-Type CD8+ T Cells
Add-back combinations which contained wild type CD8+ T cells were necessary for
developing bone marrow hypocellularity (A). Although these F1 recipients developed
hypocellular bone marrow they appeared to have no significant weight loss compared to
mice that received wild-type splenocytes, suggesting decreased disease severity. Weight
loss was most robust when WT CD4+ and CD8+ T cells were infused in combination with
PKC-ζ-/- APCs (B).
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Figure 4.6. Add-Back Combinations Require WT CD8+ T cells to Induce Robust
Peripheral Pancytopenia
CBCs performed on peripheral blood samples revealed that mice that received wild-type
bulk splenocytes, WT CD8+ T cells, PKC-ζ-/- CD4+ and WT APCs, WT CD4+ CD8+ T
cells and PKC-ζ-/- APCs or WT CD8+ T cells, CD4+ T cells and KO APCs led to robust
peripheral pancytopenia both in the white (A) and red (B) cell compartments.
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Figure 4.7. Add Back Combinations Reveal a Novel Role for PKC-θ in APCs
Resulting in T cell Infiltration
Wild-type CD8+ T cells and APCs are necessary for PKC-ζ-/- CD4+ T cells to infiltrate
into the BM cavity (A). In the absence of wild-type CD8+ T cells, CD8+ T cells failed to
infiltrate the bone marrow cavity (B). Mice induced with CD4+ wild type combinations
fail to develop disease symptoms, similar to mice induced with PKC-ζ-/- bulk splenocytes
(A&B).WT CD4+ and CD8 + T cells with PKC-ζ-/- APCs results in CD4+ and CD8+ T cell
infiltration in the BM (A&B).
*P<0.05
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Figure 4.8. PKC-θ-/- F1 mice Lack PKC-θ Protein
To verify that F1 PKC-ζ-/- mice lacked PKC-ζ protein expression, cell lysates were
generated from splenocytes from F1 controls and F1 PKC-ζ-/- mice and run on a western
blot that was probed for PKC-ζ (Santa Cruz), and β-actin (Sigma) (A). Relative
expression was normalized using β-Actin as loading control and values were determine
using Image J software (B).
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Figure 4.9. F1 PKC-θ-/- Mice Develop Disease Comparable in Severity to that of F1
Control Mice
F1 recipient mice that were or were not deficient in PKC-ζ developed disease symptoms
similarly. Both group of mice had hypocellular bone marrow (A), weight loss (B), and
peripheral pancytopenia (C&D). T cells infiltrated the BM with similar penetrance and
there were similar amount of circulating IFN-γ and TNF at the time of harvest (E).
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Figure 4.10. Rottlerin Inhibits the Phosphorylation of PKC-θ in vivo
Mice were treated with rottlerin for 5 days at a concentration of 20mg/kg per day. CD4+
T cells were then isolated from DMSO or rottlerin-treated mice and stimulated with plate
bound anti-CD3 and anti-CD28 for 48 hours. Samples were lysed and a western blot was
run. Blots were incubated with a phospho-PKC-ζ antibody (Cell Signaling). Mice that
received rottlerin treatment had decreased phosphorylation of PKC-ζ.
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Figure 4.11. Treatment with Rottlerin Results in Complete Disease Abrogation
Daily treatment with rottlerin at a dose of 10mg/kg/ beginning 1hr post-induction resulted
in normal BM cellularity (A), no weight loss (B) and no signs of peripheral pancytopenia
(C&D). Treatment also prevented T cell infiltration into the BM cavity (E) and inhibited
the production of IFN-γ and TNF (F&G).
**P<0.01, ***P<0.001
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Figure 4.12. Rottlerin Inhibits only Activated T cells
Activated donor T cells are reduced in mice treated with rottlerin based on GFP
expression as determined by flow cytometric analysis (A). Additionally mice that were
induced with AA and treated with rottlerin had similar percentages of CD4 and CD8 T
cells in the spleen as irradiated, untreated controls, demonstrating that rottlerin had no ill
effects on the host T cells during treatment (B).
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Figure 4.13. Rottlerin has Powerful Therapeutic Potential
Mice were induced with AA and began to receive rottlerin treatment beginning at day 10
post disease-induction at a dose of 20mg/kg daily. Treated mice had increased BM
cellularity (A), decreased weight loss (B) and increased level of circulating white (C)
and red blood cells (D). Rottlerin treatment decreased T cell infiltration into the BM
cavity (E).
*P<0.05, **P<0.01
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CHAPTER 5
HUMANIZING THE MODEL

5.1 Introduction

To determine if human T cells respond in a GVHD model of AA in the same way
murine T cells do, we created a humanized model of AA. We used the same strategy to
induce disease with an HLA mismatch. To create humanized mice we used NOD SCID
mice that were also lacking the gamma chain of the Il-2 receptor. These mice are capable
of being successfully engrafted with human CD34+ stem cells which leads to the
engraftment a human immune system (Shultz et al., 2005). Engraftment of human CD34+
leads to the development of human T cells, monocytes, neutrophils in these mice, but not
the development of mature B cells. CD34+ stem cell were obtained from pooled donors
leading to mice that have the potential to develop T cells of several HLA types.
To induced disease we used human peripheral mononuclear blood cells at a
concentration of 6x106 cells, delivered through an IP injection. Since there were
variations in HLA compatibility, we also saw variable disease induction. However the
development of GVHD which targeted the bone marrow allowed us to conclude that the
mechanisms which we found to be essential in the murine model of AA also regulates
disease progression in this newly defined humanized model of AA.
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5.2 Results

5.2.1 Development of Humanized Mice
At 6-8 weeks of age NOD SCID mice were reconstituted with 2x105 human
CD34+ stem cells by IV injection following a light irradiation, outlined in Figure 5.1.
Mice were then rested for 16 weeks to allow reconstitution of their immune systems.
After 16 weeks mice were bled to determine their percent reconstitution of human cells.
Peripheral blood was stained for human and mouse CD45 expression and analyzed by
flow cytometry. The percent reconstitution was determined using the formula in Figure
5.2 A. With increased time, we saw an increase in the cellularity of reconstituted mice
(Figure 5.2B). We were also able to detect CD4+ and CD8+ cells of human origin
circulating in the periphery of humanized mice, Figure 5.2 C. Using this previously
described technique we were able to successfully reconstitute NOD SCID mice with
human hematopoietic stem cells.

5.2.2 AA Induction in Humanized Mice Mimics Phenotypes seen in our Murine
Model of AA

Bone marrow failure was observed in humanized mice that were induced AA as
described in the Materials and Methods. Induced mice succumbed to disease at various
time points (between days 8-10). Although the time line varied, the disease symptoms did
not. Mice induced with disease had hypocellular bone marrow, Figure 5.3 A. Flow
cytometry analysis of the bone marrow of AA humanized mice showed decreased
expression of human CD34+ cells compared to un-induced controls (Figure 5.3B). Unlike
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normal mice humanized mice have a resident population of CD4+ and CD8+ T cells in
their bone marrow. Although humanized controls had CD4+ and CD8+ T cells in the bone
marrow we were able to detect increased expression of both of these populations in the
bone marrow of AA-induced humanized mice, based on MFI (Figure5.3 C).

5.3 Conclusions

Even though there is variability in HLA types in the humanized mice we were still
able to generate a GVH response by injecting human peripheral blood mononuclear cells.
This humanized model of disease induction recapitulated disease symptoms that were
observed in our murine model of AA, such as decreased bone marrow cellularity, loss of
stem cells and increased infiltration into the BM of human T cells. Additional steps such
as HLA typing the humanized mice would be valuable when creating the HLA mismatch
when inducing AA. Further characterization of this model is necessary to establish if
Notch and PKC-ζ play a role in disease progression. We could also use this model to
validate the therapeutic benefits of GSI and rottlerin on human cells in this AA model.
This humanized mouse model would bring murine models one step closer to clinical
relevance.
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Figure 5.1. Schematic of Humanizing Mice
NOD SCID mice were humanized using pooled CD34+ human cord blood (Stem Cell
Technology). Mice were rested for 4-6 months after reconstitution, at which time animals
were bled and the percent reconstitution was determined.
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Figure 5.2. Mice were Successfully Reconstituted with a Human Immune System
Percent reconstitution was determined based on the percent of human CD45+ cells
compared to murine CD45+ cells at two time points (A). Bone marrow cellularities were
also evaluated at these time points (B). Of the circulating human CD45+ T cells there
were robust percentages that were CD4+ or CD8+ (C).
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Figure 5.3. Induction of AA in Humanized Mice
Disease was induced using human PBMCs. Mice were then monitored for signs of
disease and were harvested when they were considered moribund, between days 10-12.
Mice induced with disease had decreased BM cellularity (A) and decreased expression of
CD34+ cells (B). Additionally there was an increase in the expression of CD4+ and CD8+
T cells in the BM (C).

104

CHAPTER 6
CONCLUDING REMARKS

The process that converts T cells from friend to foe is a long mysterious road that
remains unclear in the case of aplastic anemia. There are so many molecules and
mechanisms that are required to operate properly in order to maintain self-tolerance.
When taking all of details into account it is quite impressive that in most circumstances
the immune system functions so flawlessly. Continued research in the field of AA will
lead to a better understanding of disease pathogenesis and possibly the identification of
the causative antigen(s). Since people come into contact with so many different
pathogens it is likely that there is no single target antigen that results in AA, therefore the
establishment of models in which there is little variation in T cell response, but the
pathology of disease is maintained, make excellent tools with which to study mechanisms
of disease.
The development of this murine model of bone marrow failure as described in
Chapter 2, replicates the disease pathology seen in AA patients. In addition to showing
the same disease pathology it is also likely that the T cells mediating the disease
progression are programmed to respond to the MHC mismatch in a mechanism that is
similar to the production of autoreactive T cells. This theory is validated by the
observation that T cells isolated from our AA mice share a gene expression profile that is
similar to T cells isolated from AA patients (Figure 2.4). Using a model similar to ours
led to the discovery of adjunct immunosuppressive therapies that are used clinically
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(Bloom et al., 2004). Thus, these results demonstrate the relevance of animal models to
the discovery of clinical therapeutics.
Using our model of AA we have demonstrated the importance of the cell surface
receptor Notch1, in disease progression. Notch1 is necessary for robust disease onset and
a delayed response is observed when N1KO splenocytes are transferred, this results most
likely from impaired T cell activation and polarization. Loss of Notch1 appears to cause
this delay by modulating the protein expression of T-bet and Granzyme B, which have
both been shown to play a role in disease progression in patients with AA (Solomou et
al., 2006, Franzke et al., 2006).
Furthermore, we were able to target Notch1 therapeutically through
administration of GSI. Currently GSI is being used in clinical trial in the hopes of
alleviating disease symptoms associated with Alzheimer’s Disease and many different
forms of cancer. Some clinical studies found that there were complications regarding gut
toxicity, but the GSI which was used in these studies (LY411,575) had no detrimental
effects on the small or large intestines (Searfoss et al., 2003, Milano et al., 2004, Tosello
and Ferrando, 2009). GSI treatment in our model of AA appeared to be superior to
genetic inhibition of Notch1 because GSI was able to abrogate additional targets that
were not affected by the absence of Notch1 (Figure 3.12-3.16). Studies validating a
regimen of GSI in combination with ATG would be a great addition to these studies. Due
to the inability to obtain ATG we were not able to evaluate the effects of GSI when used
in conjunction with ATG, but these would be excellent studies to highlight GSI as a
possible adjuvant therapeutic for AA. Another benefit of GSI as a therapeutic is that long
treatment showed no harmful effects on hematopoiesis, or the ability of stem cells to
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engraft in a GSI-treated receipient mouse. GSI treatment could be used in BMT patients
with the added benefit that decreasing Notch activity also decreases GVH response
(Figure 3.19-3.22).
Interest in PKC-ζ as a possible player in disease progression of AA developed
from the observation that PKC-ζ knockout mice had decreased Notch1 expression and
impaired production of IFN-γ (Lisa Minter, unpublished data). Therefore we
hypothesized that inhibition of PKC-ζ would reduce disease severity. However, the loss
of PKC-ζ not only reduced disease severity but completely abrogated disease. Inhibition
of PKC-ζ prevented the donor T cells from becoming activated, expanding and
infiltrating the bone marrow, as described in Chapter 4.
In addition to investigating the role of PKC-ζ in donor splenocytes we furthered
these studies by investigating the individual T cell subsets and APCs. We found in these
studies that intact PKC-ζ was essential in mediating CD8+ T cell destruction.
PKC-ζ in the CD8+ T cells and APC populations was also critical for the infiltration and
expansion of PKC-ζ-/-CD4+. In all combinations, intact PKC-ζ was needed in both T cell
subsets and not necessary in the APC compartment to mediate the same level of disease
seen in WT induced mice. Loss of PKC-ζ in both T cell subsets, in combination with WT
APCs, resulted in no disease. In conjunction with these studies we addressed whether
loss of PKC-ζ in recipient mice showed any phenotype. We observed no differences in
disease pathology between PKC-ζ-/- F1 recipients and WT F1 mice.
Loss of PKC-ζ resulted in dramatic loss of T cell function, therefore, we also
examined the benefits of therapeutically inhibiting PKC-ζ. Incredibly, we were able to
maintain the same disease inhibition by using an inhibitor of PKC-ζ, rottlerin, that we
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saw in our genetic studies. Rottlerin was well-tolerated and although it had dramatic
effects on the T cells that became activated there were no ill effects on the number of
circulating host T cells (Figure 4.12). Rottlerin was effective in disease prevention even
when begun at day +10 post-disease induction, which demonstrates its therapeutic
capacity. Rottlerin or other PKC-ζ inhibitors could serve as other potential therapeutics
that would lead to prevention of T cell activation, expansion and polarization in the
treatment of AA and other autoimmune disorders.
Taking models of human disease to the next level can be done by utilizing
humanized mice. In the case of blood disorders we can take advantage of the ability to
grow and differentiate human blood cells in NOD SCID mice. These mice will allow the
engraftment of human stem cells and subsequently human hematopoiesis. Mice that
produce these human cells are an excellent model for studying human T cell responses.
Taking advantage of such technology has allowed us to begin development of a
humanized model of AA, which mimics the acute, BM-specific GVH response we
demonstrated in the AA murine model. Preliminary data outlined in Chapter 5
demonstrates that this system would be beneficial in evaluating targets such as Notch1
and PKC-ζ in human T cells. This humanized model would also create an effective way
to evaluate human T cell response to therapeutic treatments with GSI or rottlerin. The
production of models that are half mouse and half human will combine the clinical
relevance of human disease into the convenience of animal models providing researchers
with the best of both worlds.
There are still many aspects of T cell activation in response to self-antigen that are
not completely described. From these studies we propose that both Notch1 and PKC-ζ
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play a role in the T cells’ ability to mediate destruction in autoimmune disease to varying
degrees. In conclusion, Notch1 plays a role in the disease progression of AA, while PKCζ is indispensible for T cell mediated destruction. Both of these pathways most likely
function through the activation of NF-κB but may also have other distinct reinforcing
mechanisms. More studies will need to be done to determine the exact mechanisms of
how Notch1 and PKC-ζ interact, but it has been suggested that there is a relationship
between both molecules that is instrumental in T cell-mediated autoimmune disorders.
Further studies will be necessary to determine precisely what this relationship entails.
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Figure 6.1. Model of Disease
Both Notch1 and PKC-ζ play a role in disease induction. Notch1 appears to aid in disease
development, while PKC-ζ is required. Both molecules interact through NF-κB activity,
but direct interaction between one another remains undefined. Loss of either protein
results in decreased disease severity in our murine model of AA.
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CHAPTER 7
MATERIALS AND METHODS

7.1 Animals

F1 progeny were obtained by crossing Balb/C female with C57BL/6 male, off
spring were used in experiments between 9-12 weeks of age. Notch1 conditional floxed
mice were obtained by crossing Notch1fl/fl (Notch1tm2Rko/GridJ) to MxCre+/- (B6.CgTg(Mx1-cre)1Cgn/J) from Jackson Laboratory (Bar Harbor, ME.). Homozygous Notch-1
fl/fl

females were mated to Notch1fl/fl x MxCre+/- male mice to maintain breeding pairs.

C57BL/6 GFP+/- mice were originally obtained from Jackson Laboratory (Bar Harbor,
ME), were maintained by crossing C57BL/6 wild type females with GFP+/- males. PKCζ-/- were created on a C57BL/6 background and were maintained as homozygous
breeding pairs, mice were originally received as a gift from Dan Littman. PKC-ζ-/- mice
were crossed with GFP+/- to obtain homozygous PKC-ζ-/- GFP+/- mice. PKC-ζ-/- F1
hybrids were created by crossing PKC-ζ-/- male mice with female Balb/C to obtain F1
progeny that was heterozygous for the PKC-ζ allele. The second generation was created
by brother sister mating. Homozygous PKC-ζ -/- knockout mice were haplotyped using
for H2b and H2d by flow cytometry. H2b PKC-ζ-/- females were crossed with H2b males to
create progeny that were homozygous for the PKC-ζ allele and had a haplotype of H2b
and H2d, these mice are thus referred to as PKC-ζ-/- F1 mice. Crosses between haplotyped
F1 x F1 hybrids were used as controls in these studies. NOD SCID
(NOD.Cg-PrkdcscidIL2rgtm1Wjl/SzJ) breeding pairs were purchased from Jackson
Laboratory (Bar Harbor, ME), and maintained as a homozygous colony. In order to keep
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mice clear of pathogens, mice were placed on acidified, antibiotic water. All mice were
housed in the animal care facility at the University of Massachusetts Amherst in
accordance with IACUC guidelines.

7.2 Bone Marrow Failure Inductions

Balb/C and C57BL/6 F1 progeny were irradiated with 3Gy of irradiation from a
selenium source. Four to six hours later mice received an IP injection with 5x107 bulk
splenocytes from an age- and gender-matched donor. Mice were monitored daily for
signs of disease until harvested on day 17 or, in survival studies, mice were sacrificed
when they were found to be moribund (not able to take food or water) and were
considered lethally-induced.

7.3 Bone Marrow Failure Harvest

Mice were euthanized using CO2. At time of harvest, final weight was recorded and
peripheral blood was harvested using cardiac puncture through a heparinized 21gauge
needle. Liver, sternum, spleen and small intestines were collected for histology. Bone
marrow was pulverized using a mortar and pestle in a PBS 5% FBS solution. Splenocytes
were isolated by manipulation through a 40μM filter. Red blood cells were lysed using
ACK lysis buffer and white blood cells were counted.
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7.4 In Vivo Floxing of Notch-1
Notch1fl/fl x MxCre+/- mice and Notch1fl/fl x MxCre-/- mice were given 5 IP injections of
Poly(I)-Poly(C), Amersham Biosciences (Piscataway, NJ), at a dose of 12-15 μg per
gram of weight every other day. Notch1fl/fl x MxCre+/- control mice were given equal
amounts of PBS vehicle. Mice were then rested for 3 weeks after the last injection before
being used in experiments.

7.5 In Vivo Administration of GSI

7.5.1 Pretreatment Studies

Mice were fed either Harlan-Tekland mouse/rat chow formulated with the gamma
secretase inhibitor (LY 411,575) formulated to deliver 5mg/kg/day or control chow. Mice
were put on GSI chow beginning two weeks prior to disease induction and maintained to
GSI chow until harvest date. In injection studies mice received IP injection of GSI
411,575 dissolved in DMSO at a dose of 5mg/kg/day beginning three days before disease
induction and every day after, control mice received an equal volume of 50μL DMSO.

7.5.2 Treatment studies

Mice were given daily IP injections of GSI(LY 411,575) or DMSO starting at day 5
after disease induction until harvested at day 17.
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7.6 In Vivo Administration of Rottlerin

On the day of induction mice received 10mg/kg/day of Rottlerin (Sigma) IP
beginning one hour post disease-induction. Control mice received 50μL of DMSO by IP
injection daily. In treatment studies, mice began receiving Rottlerin treatment at day +10
post disease-induction at a dose of 20mg/kg daily.

7.7 GSI Long-Term Treatment and Lethal Irradiation and Reconstitution
C57BL/6 GFP+/- mice were fed control or GSI chow for 6 months beginning at 6
weeks of age. Recipient C57BL/6 mice received 12gys of gamma irradiation from
selenium sources split into two doses: 8Gys followed by a three hours rest before the
remaining 4Gys. Mice then received an IV injection of 2x106 total bone marrow cells
from long-term GSI-treated mice. Recipient mice were maintained on acidified antibiotic
water and monitored daily for signs of failed engraftment. The first group of transplanted
mice were allowed to reconstitute for 4 months, before being euthanized and transplanted
into a second group of mice that were allowed to reconstitute for another two months.
During the reconstitution period some mice were placed on GSI chow. Due to
complications of irradiation-induced dermatitis some mice were treated with silver nitrate
cream.

7.8 Clonogenic Assay

Isolated bone marrow cells were seeded in MethoCult media at concentration of
2x104 per well and plated in duplicate. Plated samples were incubated for 12-14 days at
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37o in a humidified chamber. Colonies were counted and identified according to the
manufactures protocol (Stem Cell Technology).

7.9 Reconstitution of NOD SCID mice
Human CD34+ cells were purchased from StemCell Technologies. Cells were
thawed and washed twice in PBS before being injected into NOD SCID mice. Twenty
four hours prior to injections mice received 1.3 Gys of irradiation from a selenium
sources. Mice received 2x105 CD34+ Human stem cells IV injection. Human CD34+ cells
engrafted for 4 weeks at which time peripheral blood was collected stained for human
and murine CD45+, and analyzed by flow cytometry. Percent of reconstitution was
determined using the flowing equation (% human CD45+ / (% human CD45+ % mouse
CD45+)).

7.10 Induction of Bone Marrow Failure in Humanized Mice

On the day induction mice received 1.3 Gys of irradiation, mice were the rested for
4-6 and then received an IP injection of 6x106 Human PBMC’s (StemCell Technology).
Mice were monitored for disease progression and sacrificed when mice were determined
to be moribund.

7.11 Histology

Sternums, spleens, livers and small intestines were harvested on day 17 and fixed in
10% neutral buffered formalin overnight (VWR). Sternums were then decalcified for an
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additional two days in Cal-rite (Richard Allen Scientific). Samples were then stored in
70% Et-OH at 4oC until they were sent to Pioneer Valley Life Sciences Institute where
they were paraffin-embedded and stained with hematoxylin and eosin.

7.12 Surface and Intracellular Flow Cytometry
Isolated bone marrow and spleen cells were counted and resuspended in 100μL of
FACS wash buffer (0.2% BSA in PBS) at a concentration of 1x106 per sample or less.
Staining was done in a V-bottom plate as follows, surface staining at a dilution at 1:100
dilution for 20 minutes at 4oC protected from light. Cells were washed twice with FACS
was buffer cells were then fixed and permeabilized for 30 minutes at 4oC using the Foxp3
intracellular staining kit (BD). Cells were then washed twice with perm wash buffer and
then intracellular stained at a dilution of 1:50 in perm wash buffer for 30 minutes at 4oC
protected from light. Cells were washed twice more and then resuspended in FACS wash
buffer and acquired on LSRII flow cytometer with FACS Diva software (BD). Analysis
of FACS data was done using FACS Diva (BD Bioscience) or FlowJo (Tree Star)
software. A complete list of antibodies can be found in Table 7.1.

7.13 Cytometric Bead Array

Cytokine levels were determined in plasma using either the Th1/Th2 or
Th1/Th2/Th17 cytometric bead array kit (BD Bioscience), following manufactures
protocol. Plasma samples were acquired on a LSRII and analyzed using FCAP array
software (BD Bioscience).
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7.14 In vitro T cell Isolation and Activation
Spleens were isolated and manipulated through a 40μM filter; splenocytes were
treated with ACK lysis buffer to remove red blood cells. CD4 and CD8 T cells were
isolated using CD4/CD8 T lymphocyte IMAG system (BD Biosciences). Cells were then
plated at 2.25-3x106 cells in a 12-well antibody-coated plate. Plates were coated with
anti-CD3ε and anti-CD28 as follows, anti-hamster IgG (Sigma) incubated at room temp
on a rocker for 2 hours. Anti-hamster was removed and replaced with 120μL of antiCD3ε and anti-CD28 and incubated over night at 4oC on a rocker. Anti-CD3ε and antiCD28 were purified from 145-2c11and 37N hybridoma cell lines by Becky Lawlor. Tcells were polarized toward a Th1 phenotype using 1ng/mL of murine IL-12 and of antiIl-4 antibody.

7.15 RNA Isolation and QPCR

RNA was isolated using the RNAqueous kit (Ambion) following the manufacture
protocol. Concentration of RNA was determined by nanodrop analysis. RNA sample
yielding less than 60ng/μL were concentrated using the RNA easy kit (Qiagen). cDNA
was synthesized using 1μg of RNA 1.2μL of dNTPs (Roche Applied Science), 2μL of MMuLV reverse transcriptase buffer (New England Biolabs), 1μL of olig-DT (12-18)
(Invitrogen), 1μL RNase inhibitor (Promega) and 1μL of 200.000 U/mL M-MuLV
reverse transcriptase (New England Biolabs). Thermocycler program: 42oC for 45
minutes, 65oC for 10 minutes. qRT-PCR was performed using 1μL of cDNA for in vivo
generated samples or 1μL of a 1:10 diluted cDNA for in vitro generated samples.
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Samples were run in duplicate on a MxPRO 3000 (Stratagene) and prepared as follows:
10μL of SYBR green mix (Takara), .4μL of 10μM stock of both forward and reverse
primers and 8.2μL of water. All samples were run using the subsequent program: 95o 5
minutes, 35 cycles of: 95o 25 seconds 62o 25 seconds, 95o 1 minute, 62o 1 minute, 95o 30
seconds. Data was analyzed using MxPro3005p software (Stratagene) and quantified
using the delta delta Ct method. β-Actin was used as the housekeeping gene for
normalization and relative expression was determined to a naïve control. A table of the
QPCR primer can be found in Table 7.2.

7.16 Western Blotting

Western blot were performed using standard techniques. Briefly, lysates were
prepared in a presenillin lysis buffer for 30 mins with rocking. Protein concentration was
determined using a BSA kit (Pierce) following the manufactures protocol. Samples were
run on an 8% gel and transferred to a nitrocellulose blot. Blots were blocked for 1hr at
room temp in Blotto. The following antibodies were used for western, β-Actin Ac-40 at
1:7500 (Sigma), PKC-ζ 212 1:1000 (Santa Cruz) and Phospho-Thr583 PKC-ζ 1:1000
(Cell Signaling). Blots were incubated with the proper secondary HRP conjugated
antibodies for 30 minutes at room temp. Blots were then developed using homemade
ECL reagents. Normalization of western blots was done using ImageJ software (Wayne
Rasband, NIH).
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Table 7.1. Antibodies used for Flow Cytometry

Mouse
FITC-Conjugated
Antigen
CD4 (L3T4)
CD8a (Ly-2)
CD25
CD26
CD34
IL-2
LFA-1 (CD11a)
TNF-α
PE Conjugated
Antigen
CD3e

Species
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse

Clone
H129.19
53-6.7
7D4
H194-112
RAM34
JES6-5H4
M17/4
MP6-XT22

Company
BD Pharmingen
BD Pharmingen
BD Pharmingen
BD Pharmingen
eBioscience
BD Pharmingen
eBioscience
eBioscience

Species
Mouse

Clone
145-2C11

Company
BD Biosciences

CD8a
CD25 (IL-2Ra, p55)
Granzyme B
H-2Kb
IFN-γ
Notch 1 (IC)
Perforin
Sca-1 (Ly6A/E)
T-bet
Ter-119
Mouse IgG1 k Isotype
Conjugated Strepavidin
PerCP Conjugated
Antigen
CD4
CD8a
CD45R/B220

Mouse
Mouse
Mouse
Mouse
Mouse
Mouse/Human
Mouse
Mouse
Mouse/Human
Mouse

53-6.7
PC61.5
GB11
AF6-88.5
DB-1
mN1A
eBioOMAK-D
D7
eBio4B10
TER-119
P3.6.2.8.1

BD Pharmingen
eBioscience
eBioscience
BD Pharmingen
BD Pharmingen
eBioscience
eBioscience
eBioscience
eBioscience
eBioscience
eBioscience
eBioscience

Species
Mouse
Mouse
Mouse

Clone
RM4-5
53-6.7
RA3-6B2

Company
BD Pharmingen
BD Pharmingen
BD Pharmingen

Conjugated Strepavidin
APC Conjugated
Antigen
CD4 (L3T4)
CD25
CD62L (Ly-22)

BD Pharmingen
Species
Mouse
Mouse
Mouse

Clone
GK1.5
PC61
MEL-4

119

Company
eBioscience
BD Pharmingen
eBioscience

c-Kit (CD117)
Mouse
Ly-6C (Gr-1)
Mouse
Antigen
Species
CD34
Mouse
T-Bet
Mouse/Human
Mouse IgG1, k Isotype Control
PE-Cy7 Conjugated
Antigen
Species
c-Kit (CD117)
Mouse
Conjugated Steptavidin
Biotinylated Antibodies
Antigen
Species
CD34
Mouse
CD69
Mouse
H-2Kd
Mouse
H-2Kb
Mouse
LFA-1 (CD11a)
Mouse
Mouse
Biotin Lineage Panel
CD3e
Mouse

2B8
RB6-8C5
Clone
RAM34
eBio4B10
P3

eBioscience
BD Pharmingen
Company
eBioscience
eBioscience
eBioscience

Clone
2B8

Company
eBioscience
eBioscience

Clone
RAM34
H1.2F3
SF1-1.1
AF6-88.5
2D7
145-2C11

Company
eBioscience
eBiosceince
BD Pharmingen
BD Pharmingen
BD Pharmingen
BD Pharmingen
BD Pharmingen

CD11b (Mac-1)
Mouse
CD45R/B220
Mouse
Ly-6G and Ly-6C
Mouse
TER-119
Mouse
Human
FITC Conjugated/Alexa Fluor 488
Antigen
Species
CD4
Human
CD45
Human
PE Conjugated
Antigen
Species
CD8
Human
550619
550619

M1/70
RA3-6B2
RB6-8C5
TER-119

BD Pharmingen
BD Pharmingen
BD Pharmingen
BD Pharmingen

Clone
OKT4
HI30

Company
eBioscience
BD Pharmingen

Clone
OKT8
550619

Company
eBioscience
550619
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Table 7.2. qRT-PCR primers

Symbol
Actb
Gzmb
Hes1
Ifng
Il12rb2
Notch1
Notch2
Notch3
Pf4
Prf1
Rbpj
Tnf

Ref. ID
NM_00
7393
NM_01
3542
NM_00
8235
NM_00
8337
NM_00
8354
NM_00
8714
NM_01
0928
NM_00
8716
NM_01
9932
NM_01
1073
NM_00
9035
NM_01
3693

5´ Primer
Primer sequence
GGCTGTATTCCCCTCCATCG

3´ Primer
Primer sequence
CCAGTTGGTAACAATGCCATGT

Size
154

CCACTCTCGACCCTACATGG

GGCCCCCAAAGTGACATTTATT

142

CCAGCCAGTGTCAACACGA

AATGCCGGGAGCTATCTTTCT

166

ATGAACGCTACACACTGCATC

CCATCCTTTTGCCAGTTCCTC

182

AGAGAATGCTCATTGGCACTT
C
CCCTTGCTCTGCCTAACGC

AACTGGGATAATGTGAACAGC
C
GGAGTCCTGGCATCGTTGG

178

ATGTGGACGAGTGTCTGTTGC

GGAAGCATAGGCACAGTCATC

146

TGCCAGAGTTCAGTGGTGG

CACAGGCAAATCGGCCATC

157

GCCTGCACTTAAGAGCCCTA

GATCTCCATCGCTTTCTTCG

199

AGCACAAGTTCGTGCCAGG

GCGTCTCTCATTAGGGAGTTTT
T
GGACAAGCCCTCCGAGTAGT

151

TTGGTGGTTTGTGAGTGTGAG

228

ATGCCCTCCGGTTTTCCTC
GACGTGGAACTGGCAGAAGA
G
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